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DEFINING THE FUNCTIONS OF USP22 AND USP44 IN REGULATION OF H2BUB1 
LEVELS 
Xianjiang Lan, Ph.D. Candidate 
 
Supervisory Professor: Sharon Dent, Ph.D. 
        Aberrant levels of histone ubiquitination are involved in various human diseases 
including neurodegenerative disorders and cancers. Particularly, Histone H2B 
monoubiquitination (H2Bub1) is highly associated with gene regulation in both normal 
cells and diseases. Many deubiquitinases (mainly USPs) are defined to regulate global 
H2Bub1 levels. However, how these USPs are regulated and how they contribute to 
diseases are not well understood.  
        USP22, part of the deubiquitination module (DUBm) in the SAGA complex, is a 
well-defined regulator of H2Bub1 levels. ATXN7, another crucial subunit of the SAGA 
DUBm, is involved in a neurodegenerative disease, spinocerebellar ataxia type 7 (SCA7), 
due to a polyglutamine (polyQ) expansion in its N-terminal region. Given the allosteric 
regulation of USP22 DUB activity within the DUBm, whether and how the polyQ 
expansion in ATXN7 affects SAGA DUB activity was not known.  To address this 
question, we reconstituted the SAGA DUBm in vitro with wild type ATXN7 or the 
ATXN7polyQ mutant.  We found that the DUBm has minimal activity in the absence of 
ATXN7. ATXN7-92Q, which corresponds to a pathogenic form of the protein, is largely 
insoluble unless it is incorporated into the DUBm. Importantly, we demonstrated that 
ATXN7-92Q enhances DUB activity to a similar extent as WT ATXN7. Consistent with 
these in vitro results, co-overexpression of DUBm components in human astrocytes 
promotes the solubility of ATXN7-92Q, and greatly inhibits its aggregation into nuclear 
inclusions that sequester other DUBm components including ATXN7L3, leading to global 
increases in H2Bub levels. Co-overexpression of ATXN7L3 and ENY2 with ATXN7-92Q 
reverses this effect. Finally, we found that global H2Bub levels are increased in 
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cerebellums taken from a SCA7 mouse model, consistent with reduced DUB activity in 
the presence of ATXN7 polyQ mutant. Taken together, our study suggests that ATXN7-
polyQ expansions do not change the biochemical activity of the DUBm, but they likely 
contribute to SCA7 by initiating aggregate formation that sequesters DUBm components 
away from H2B and other substrates. To further study the contribution of the DUB 
activity of USP22 to SCA7 disease, we also planned to delete USP22 in Purkinje cells 
and Bergman glia, both of which are involved in the pathogenesis of SCA7 disease, 
through establishing a FloxP-Usp22 mouse model. We generated Usp22FloxFRT mice 
by in vitro fertilization using sperm obtained from the Knock Out Mouse Project  (KOMP). 
After crossing with FLpase mice, we obtained the Usp22Flox mouse model. Currently, 
we are crossing Usp22Flox mice with Pcp2-Cre and GFAP-Cre mice, which will 
specifically delete Usp22 in Purkinje cells and Bergman glia, respectively. We will 
analyze the potential “Ataxia” phenotypes of the mice with Usp22 deletion in Purkinje 
cells or Bergman glia. 
        Similar to USP22, USP44 is also involved in H2Bub1 regulation. The USP44 
deubiquitinase is implicated in various biological processes including ES cell 
differentiation, DNA damage repair, and cancer development. However, USP44 alone is 
not active, and whether USP44 directly deubiquitinates histone H2B and what other 
partners are required for its DUB activity are not known. Using tandem affinity 
purification and Multidimensional Protein Identification Technology (MudPIT), we 
identified USP44 as an integral subunit of the Nuclear receptor co-repressor complex (N-
CoR complex). As part of N-CoR, USP44 deubiquitinates H2B in vitro and in vivo. 
Depletion of USP44 impairs the repressive activity of N-CoR complex targeted to a 
chromatinized luciferase reporter. ChIP-qPCR experiments indicate that USP44 is 
recruited to the promoter of luciferase reporter, leading to decreased H2Bub levels.  
These data indicate that USP44 and HDAC3 work together within N-CoR, to repress 
vi 
transcription of target genes. Furthermore, USP44 expression is higher, and H2Bub1 
levels are lower, in MDA-MB-231 triple negative breast cancer cells than in MCF-10A 
cells.  Depletion of USP44 impairs invasiveness of MDA-MB-231 cells in vitro and leads 
to an increase of global H2Bub1 levels, as does depletion of another essential subunit of 
NCoR, TBL1XR1. Together, our findings indicate that USP44 and N-CoR may contribute 
to metastatic behaviors of triple negative breast cancer cells. 
        In summary, both USP22 and USP44 participate in multiple biological processes 
through modulating H2Bub1 levels and defective activity of these DUBs likely contributes 
to various human diseases. Our data highlight the importance of appropriate DUB 
activity and H2Bub1 levels for normal cell growth and behavior. 
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Chapter 1: Introduction 
 
1.1 DUBs   
 
          There are around 95 deubiquitinating enzymes (DUBs) encoded by the human 
genome (Nijman et al., 2005). These DUBs are grouped into five major classes 
according to sequence homology: Ubiquitin-Specific Proteases (USPs), Ubiquitin C-
Terminal Hydrolases (UCHs), Machado-Joseph Disease Protein Domain Proteases 
(MJDs), Ovarian Tumor Proteases (OTUs), and JAMM Motif Proteases (Figure 1) (Sowa 
et al., 2009). USP class represents the major DUBs in human genome. As the names 
indicate, all the USPs contain USP domain which possesses two short and well-
conserved motifs, called Cys and His boxes, where the critical residues for catalysis 
locate (Sowa et al., 2009). USP22 and USP44 belong to the USP class. Both of USP22 
and USP44 have been shown to regulate H2Bub1 levels, however, the molecular 
mechanism of USP22 and USP44 involved in diseases through modulating H2Bub1 
remains to be known.  
 
 
1.1.1 USP22 and USP44 
         USP22, an enzymatic subunit of the DUB module in the SAGA complex, functions 
to deubiquitinate histone H2Bub1 and other non-histone substrates including TRF1, 
FBP1 and Sirt1 (Atanassov and Dent, 2011; Atanassov et al., 2009; Lin et al., 2012; 
Zhang et al., 2008; Zhao et al., 2008). Importantly, recombinant USP22 alone is not 
active. Associations with other components of the DUB module including ATXN7, 
2 
ATXN7L3 and ENY2 are required for its full DUB activity (Lan et al., 2015; Lang et al., 
2011).  
         The USP44 deubiquitinase also belongs to USP class. USP44 plays important 
roles in ES cell differentiation, DNA damage repair, cell cycle regulation and cancer 
development (Fuchs et al., 2012; Liu et al., 2015; Mosbech et al., 2013; Stegmeier et al., 
2007; Zhang et al., 2012). USP44 was reported to regulate centrosome positioning 
through interaction with CETN2 (Centrin2) (Zhang et al., 2012). Previous studies also 
indicated a major role for USP44 in regulation of the H2Bub1 levels during ES cells 
differentiation (Fuchs et al., 2012). However, similar to USP22, recombinant USP44 by 
itself is not active toward histone H2Bub1 in vitro. What are the other partners required 
for the activation of USP44 DUB activity is not known. 
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Figure 1: Phylogenetic analysis of human DUBs. 
The human genome encodes ~95 DUBs in five major classes. They are USPs, UCHs, 
OTUs, MJDs and JAMMs (see main text introduction for details). 
Figure 1 is adapted from Sowa, M.E., Bennett, E.J., Gygi, S.P., and Harper, J.W. (2009). 
Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389-403. 
Permission has been acquired from the journal to use this figure. 
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1.2 Histone modifications 
        Nucleosomes, consisting of the four core histone proteins (H2A, H2B, H3 and H4), 
are the basic functional units in eukaryotic chromatin. Histones undergo multiple post-
transcriptional modifications including methylation, acetylation, ubiquitylation, 
phosphorylation, butyrylation, formylation, citrullination, proline isomerization, ADP 
ribosylationsumoylation, propionylation, and crotonylation (Kouzarides, 2007; Tan et al., 
2011) (Figure 3). Enzymes that catalyze such modifications are named as “writers”; 
enzymes that remove a modification are named as “erasers”, and proteins that bind the 
modified histones are named as “readers” (Plass et al., 2013). Different modification 
states of the histones contribute to regulation of various biological processes, and 
dysregulation of histone modifications contribute to multiple human diseases (Cole et al., 
2015). 
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Figure 2: Histone post-translational modifications. 
Schematic drawing of a nucleosome with the four canonical histones (H2A, H2B, H3 and 
H4) and the linker histone H1. The covalent PTMs [methylation (Me), acetylation (Ac), 
ubiquitination (Ub), and phosphorylation (Ph)] are highlighted on the N- and C-terminal 
tails of each histone. 
Figure 2 is adapted and modified from Tollervey, J.R., and Lunyak, V.V. (2012). 
Epigenetics: judge, jury and executioner of stem cell fate. Epigenetics 7, 823-840. 
Permission has been acquired from the journal to use this figure. 
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1.3 PolyQ diseases 
          There are nine neurologic disorders caused by a number of CAG repeat 
expansions, typically in coding regions of different proteins. During translation, the 
expanded CAG repeats are encoded into a series of glutamine residues called 
polyglutamine tract (polyQ). These diseases include Huntington’s Disease (HD), Spinal 
and Bulbar Muscular Atrophy (SBMA), Dentatorubral-pallidoluysian atrophy (DRPLA), 
and the spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7 and 17 (Table 1) (Todd and Lim, 
2013). The polyQ tracts tend to form aggregates (Wetzel, 2012), which are the hallmark 
of many neurodegenerative diseases. However, what the role of these aggregates is in 
the pathogenesis of these diseases is highly debated. Although this group of 
neurodegenerative diseases is caused by the polyQ expansions in different unrelated 
proteins, they share a common symptom, ataxia, characterized by a progressive 
degeneration of nerve cells (Todd and Lim, 2013). Moreover, The longer the expanded 
glutamine tract is, the earlier the symptoms start and the more severe the diseases 
develop (David et al., 1998). 
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Table 1: Polyglutamine diseases 
There have been nine polyglutamine diseases identified to date. The human protein 
mutated in each disease is noted, along with a schematic of its relative size and 
glutamine (Q) expansion location (purple box and triangle). The approximate size of the 
wildtype protein is noted in kilodaltons (kDa). Polyglutamine-expanded protein size can 
vary depending on the length of the CAG repeat. The tissues principally affected in each 
disease, as well as the clinical output and the cellular locations of the inclusions are 
listed. 
This table is adapted from Todd, T.W., and Lim, J. (2013). Aggregation formation in the 
polyglutamine diseases: protection at a cost? Mol Cells 36, 185-194. 
Permission has been acquired from the journal to use this table. 
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1.3.1 SCA7 disease and SAGA complex 
         Spinocerebellar ataxia type 7 (SCA7) is one of nine polyQ diseases correlated with 
progressive neurodegeneration (Lebre and Brice, 2003; Todd and Lim, 2013). SCA7 is 
dominantly inherited and is caused by polyQ expansions within the N-terminal region of 
ATXN7. Wild type ATXN7 contains 4 to 35 glutamine (Q) residues, whereas mutant 
ATXN7 contains from more than 36 to up to 300 Q repeats (Todd and Lim, 2013). SCA7 
not only leads to progressive spinocerebellar neurondegeneration, but also a unique 
symptom of retinal degeneration. SCA7 patients display dysarthria, abnormal gait, 
uncoordinated movements and visual loss, usually followed by early death (Johansson 
et al., 1998). Although it is broadly agreed that aggregation of the expanded glutamine 
stretch plays an important role in neurotoxicity, the detailed molecular mechanism of 
toxicity remains to be known. 
        ATXN7 is a subunit of the deubiquitinase module (DUBm) in the conserved SAGA 
complex (Figure 3), which regulates gene expression via modulating histone 
ubiquitination and acetylation (Koutelou et al., 2010). ATXN7 in itself has no enzymatic 
activity. It resides within the DUB submodule of SAGA and serves to anchor this module 
to the main complex. The PolyQ expansions in ATXN7 could affect either or both of the 
enzymatic activities. Previous studies provided conflicting evidence regarding the effects 
of ATXN7-polyQ on the activity of Gcn5, the catalytic component of the histone 
acetyltransferase (HAT) module in SAGA complex (Helmlinger et al., 2006; McMahon et 
al., 2005; Palhan et al., 2005). In a SCA7 mouse model, the deletion of Gcn5 facilitates 
cerebellar Purkinje cell and retinal degeneration, indicating that Gcn5 is involved in 
SCA7 disease progression (Chen et al., 2012). However, specific deletion of Gcn5 in 
Purkinje cells is not enough to cause severe ataxia, indicating that other SAGA functions 
may also contributes to SCA7 development (Chen et al., 2012). Given that ATXN7 is a 
9 
subunit of the DUB module in SAGA, polyQ expansions might affect the deubiquitinating 
activity of SAGA. 
        In Saccharomyces cerevisiae, the SAGA DUB module consists of Ubp8, Sgf11, 
Sus1, and Sgf73 (homologs of USP22, ATXNL3, ENY2, and ATXN7, respectively, in 
humans) (Figure 3) (Helmlinger et al., 2004; Lee et al., 2005; Zhao et al., 2008). 
Sgf73/ATXN7 functions both to bridge the DUBm to SAGA through its central domain 
and to form an integral part of the DUBm through its N-terminal domain (Kohler et al., 
2008). However, Ubp8 alone is not active and other subunits of DUBm are required for 
its DUB activity. The crystal structure of the yeast DUBm provides a molecular 
interpretation about how these associations with other DUBm components are required 
to activate Ubp8 (Kohler et al., 2010; Samara et al., 2010). Similarly, the DUB activity of 
the mammalian catalytic subunit USP22 is also allosterically regulated through multiple 
interactions with human SAGA DUBm components (Lang et al., 2011). The zinc finger 
(ZnF) domain of ATXN7 is required for association with the DUBm (Lang et al., 2011). 
However, whether and how the polyQ-expanded ATXN7 affect DUBm activity or integrity 
has not been directly addressed.  
        Although other substrates for USP22 have been identified in mammalian cells 
(Atanassov and Dent, 2011; Atanassov et al., 2009), the best-characterized substrate is 
histone H2B (Zhang et al., 2008). Genome-wide analyses by ChIP-seq in human cells 
show that H2Bub1 signal is enriched in the gene body of highly expressed genes 
(Minsky et al., 2008), but this modification is involved in both gene repression and 
activation (Shema et al., 2008). For example, expression of reelin, an important factor for 
the development and maintenance of Purkinje cells, is highly downregulated in SCA7 
astrocytes, and this downregulation leads to an increase of H2Bub1 levels at the reelin 
gene promoter (McCullough et al., 2012). Together, these data suggest that the DUB 
10 
activity of USP22 may be defective in SCA7 tissues, causing dysregulation of crucial 
target genes, which contribute to SCA7 disease. 
 
Figure 3: SAGA complex is very conserved from yeast to mammals. 
SAGA complex contains both HAT module and DUB module where Gcn5 and 
USP22/Ubp8 serve as the enzymatic subunits, respectively. HAT module consists of 
Ada3, Ada2, Sgf29 and Gcn5. The DUB module consists of Sgf11, Sgf73, Sus1 and 
Ubp8.                                                                                                                           
Figure 3A is adapted and modified from Wu, P.Y., Ruhlmann, C., Winston, F., and 
Schultz, P. (2004). Molecular architecture of the S. cerevisiae SAGA complex. Mol Cell 
15,199-208.                                                                                                                
Figure 3B is adapted from Samara, N.L., and Wolberger, C. (2011). A new chapter in the 
transcription SAGA. Curr Opin Struct Biol 21, 767-774.  
Permissions have been acquired from the journals to use these figures. 
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1.4 H2Bub1 and Cancer 
        Histone H2B is monoubiquitinated on lysine 123 in yeast and the corresponding 
lysine 120 in mammals (H2Bub1). H2Bub1 appears to contribute to creation of open and 
accessible chromatin structures (Fierz et al., 2011), as it  has been reported to play 
important roles in transcriptional initiation and elongation (Henry et al., 2003; Pavri et al., 
2006; Xiao et al., 2005), mRNA 3’-end processing (Pirngruber et al., 2009), DNA 
damage response (Moyal et al., 2011), DNA replication (Trujillo and Osley, 2012) and 
maintenance of stem cell multipotency (Fuchs et al., 2012; Karpiuk et al., 2012). H2Bub1 
is required in yeast and human cells for histone H3 methylation on lysine 4 (H3K4) and 
lysine 79 (H3K79) (Briggs et al., 2002; Ng et al., 2002; Sun and Allis, 2002; Wu et al., 
2011), which further contributes to transcriptional activity.  
        H2Bub1 levels are governed by a balance in the activities of specific ubiquitin E3 
ligases, such as RNF20/40 (Kim et al., 2005), and deubiquitinases that target this 
modification (Figure 4). Several deubiquitinases including USP22 (Zhang et al., 2008; 
Zhao et al., 2008), USP27X, USP51 (Atanassov et al., 2016), USP3 (Nicassio et al., 
2007), and USP49 (Zhang et al., 2013) can remove ubiquitin from histone H2B. USP44 
has also been implicated in H2Bub1 deubiquitylation (Fuchs et al., 2012), but USP44 
alone is not active.  The importance of H2Bub1 to human health is emphasized by 
several studies that indicate H2Bub1 levels are low to absent in many aggressive 
cancers including colorectal cancer, metastatic breast cancer, testicular seminoma, 
parathyroid cancer, and lung cancer (Cao and Yan, 2012; Fuchs and Oren, 2014). 
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Figure 4: Ubiquitin ligases and deubiquitinating enzymes responsible for 
monoubiquitination of histones H2A and H2B.  
Major post-transcriptional modifications on histone H3 and H4 tails are shown. An E1 
ubiquitin (ub)-activating enzyme engages ATP to activate free ubiquitin, which is 
transferred to the active site of an E2 ubiquitin-conjugating enzyme, two of which have 
been reported to be associated with H2Bub1. E3 ubiquitin ligases work with E2 to 
transfer ubiquitin to the target protein. Four E3s, most of them appearing in RING finger 
complexes, have been identified in the H2Bub1 cascade; however, it is unclear how, or 
if, they function together for the monoubiquitination of histone H2B. Deubiquitinating 
(DUB) enzymes, of which seven have been reported to be associated with H2Bub1, 
cleave ubiquitin from its substrate.  Ac, acetylation; Me, methylation; P, phosphorylation.  
Figure 4 is adapted from Cao, J., and Yan, Q. (2012). Histone ubiquitination and 
deubiquitination in transcription, DNA damage response, and cancer. Front Oncol 2, 26 
Permission has been acquired from the journal to use this figure. 
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Chapter 2: Materials and Methods 
 
Contents of this chapter are partially based on Lan, X*., Koutelou, E*., Schibler, A.C., 
Chen, Y.C., Grant, P.A., and Dent, S.Y. (2015). Poly(Q) Expansions in ATXN7 Affect 
Solubility but Not Activity of the SAGA Deubiquitinating Module. Mol Cell Biol 35, 1777-
1787. (* Equal contribution authors) 
According to Mol Cell Biololgy, the author retains the ownership of copyright to 
reproduce the contribution or extracts from the original article.  
 
2.1 Plasmids  
 
        USP22 cDNA was acquired from Open Biosystems. ATXN7L3 and ENY2 cDNAs 
were a gift from Didier Devys. USP22, ATXN7L3, and ENY2 were subcloned into the 
2.1-TOPO vector by PCR, sequenced, and then cloned into the NruI and NotI sites of 
the baculovirus expression vector pBacPAK8 (Clontech). A hemagglutinin (HA) tag was 
introduced into pBacPAK8 in BamHI and NruI, and a Flag tag was introduced into 
pBacPAK8 in KpnI and NruI. Mutation of USP22 cysteine 185 to serine was introduced 
using a site-directed mutagenesis kit (Agilent Technologies). Full-length Flag–ATXN7-
24Q and Flag–ATXN7-92Q in the pSDM vector were provided by Patrick A. Grant. The 
cDNAs of human ATX7L3 and ENY2 were gifts from Didier Devys. The N termini of 
Flag–ATXNT7-24Q NT and Flag–ATXN7-92Q NT were subcloned into NheI and PstI of 
pBacPAK8.3. Packaging vectors (psPAX2 and pMD2G) and transfer vectors containing 
full-length Flag–ATXN7-24Q or Flag–ATXN7-92Q, which were used for production of 
recombinant lentivirus, were provided by Patrick A. Grant. The full-length Flag or V5-
tagged ATXN7L3 and ENY2 expression constructs were generated in pSDM101 with 
MluI and NdeI by using a PCR cloning strategy with pBacPAK8-ATXN7L3 and 
pBACPAK8-ENY2 as the templates, respectively. pINTO-NFH vector and pINTO-GAL4 
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vector were gifts from Dr. Danny Reinberg lab as described previously (Gao et al., 2014; 
Gao et al., 2012). pCAG-C-FH vector was a gift from Dr. Taiping Chen lab. USP44 
cDNA was a gift from Dr. Paul J. Galardy lab. CETN2, TBL1X and TBL1XR1 cDNAs 
were purchased from Open Biosystems (GE Healthcare). These cDNAs were further 
subcloned into pINTO-NFH, pINTO-GAL4 or pCAG-C-FH vectors. For truncated GAL4-
TBL1XR1, PCR was used to amplify the fragments of interest before insertion to the 
pINTO-GAL4 vector. For protein expression in insect cells, cDNAs of interest were 
subcloned into pBacPAK8.3 vectors, Production of recombinant viruses and Sf21 cell 
infection were performed following the manufacturer's protocols (BD Biosciences). 
 
 
2.2 Antibodies 
 
        The details of all the antibodies used in this study are described in table 1 
 
 
2.3 Cell lines 
         
           Primary human astrocytes (N7805-100; Life Technologies) were grown in 
Dulbecco modified Eagle medium (DMEM) supplemented with 1% N-2 supplement and 
10% fetal bovine serum (FBS) (Life Technologies). Artificially immortalized human 
astrocytes were provided by Patrick A. Grant and grown in alpha minimal essential 
medium (Life Technologies) supplemented with 10% FBS (Life Technologies). 293T, 
293T-REx-luciferase and MDA-MB-231 cells were maintained in high-glucose 
Dulbecco’s Modified Eagle Medium (DMEM-H) (Thermo Scientific) supplemented with 
10% Fetal Bovine Serum (FBS) (HyClone, Cat. # SH30910.03) and 1% penicillin-
streptomycin (Thermo Scientific). MCF10A cells were provided by Dr. Khandan 
Keyomarsi and were grown in 1:1 mixture of alpha-Medium (Minimum Essential Medium 
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alpha (Corning, Cat. # 15-012-CV) and Ham’s F-12 medium (Corning, Cat. # 10-080-CV) 
supplemented with 1% FBS, 10mM HEPES, 2 mM glutamine, 1 g/ml hydrocortisone, 
12.5 g/ml epidermal growth factor (EGF), 1 g/ml insulin, 35 g/ml bovine pituitary 
extract (BPE), 10 g/ml ascorbic acid, 0.2 nM -estradiol, 2.5 ng/ml Na selenite, 6.65 
ng/ml triiodothryonine III, 0.0006% ethanolonine, 14.1 g/ml phosphoethanolanine (PE), 
and 10 g/ml transferrin. Cells were maintained in CO2 incubator at 37C and 5% CO2. 
Sf21 insect cells were grown in Sf-900TM II SFM (Life Technologies, Cat. # 10902-096) 
supplemented with 1% penicillin-streptomycin. Cells were maintained in flasks (Corning, 
250 mL Cat. # 431144 or 500 mL Cat. # 431145) on an orbital shaker at 120 rpm, 27 C.  
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Antibody Suppliers Cat. # Applications 
Anti-TBL1X Proteintech 13540-1-AP WB/IP 
Anti-TBL1XR1 Bethyl Laboratories A300-408A WB 
Anti-NCOR1 Bethyl Laboratories A301-145A WB 
Anti-HDAC3 Bethyl Laboratories A300-464A WB 
Anti-CETN2 Proteintech 15877-1-AP WB 
Anti-USP44 Santa Cruz Sc-292324 WB 
Anti-USP22 Home made 3933-1 WB 
Anti-GAL4 Millipore 06-262 ChIP 
Anti-GAL4 Santa Cruz Sc-510 WB 
Anti- FLAG beads Sigma A2220 IP 
Anti-HA beads Roche 11815016001 IP/ChIP 
Anti-TBL1X Santa Cruz Sc-11391 WB 
Anti-beta-Tubulin Cell signaling 2146 WB 
Anti-beta-actin Santa Cruz Sc-47778 WB 
Anti-FLAG (M2) Sigma F3165 WB 
Anti-HA (12CA5) Roche 11583816001 WB 
Anti-H3 Millipore 06-755 WB/ChIP 
Anti H2A Millipore 07-146 WB  
Anti-H2B Millipore 07-371 WB/ChIP 
Anti-H2Bub (K120) Millipore 05-1312 WB/ChIP 
AntiH2Aub (K119) Millipore 05-678 WB 
Anti-H3K9/14ac Millipore 06-599 WB/ChIP 
Anti-Rabbit-HRP GE Healthcare NA934-1ML WB 
Anti-Mouse-HRP GE Healthcare NA931-1ML WB 
Anti-V5 Invitrogen 46-0705 WB/IF 
Anti-ATXN7L3 (Zhao et al., 2008) 2325 IF 
Alexa Fluor 488-conjugated Anti-
rabbit 
Life Technologies A-11034 IF 
Alexa Fluor 594-conjugated Anti-
mouse 
Life Technologies A-11005 IF 
         
Table 2: Antibodies used in this study 
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2.4 Baculovirus expression system  
        Baculovirus transfection, infection, and maintenance were performed as previously 
described (Lan et al., 2015). In 60 mm plastic dishes, 2x106 Sf21 cells were co-
transfected with 3 µg of pBacPAK8.3 expression vectors, containing the indicated 
cDNAs, and 0.5µg of linearized baculovirus DNA (BestBac 1.0, Expression systems, 
Cat. # 91-001) using Lipofectamine 2000 or FuGENE® 6 (Promega, Cat. # E2691) 
following manufacturer’s instructions. 3 days post the transfection, the medium 
containing the recombinant viral particles were collected. To increase the titer of the 
virus, this medium was further used (in 1:4 dilution) to infect new Sf21 cells for several 
times. For infection, exponentially growing Sf21 cells were seeded in 15 cm plastic 
dishes (2x107 cells/dish) and viral medium was added after the cells were attached to 
the dish (~15 min to attach). Cells were incubated in a humidity chamber (plastic box 
with wet paper towels at the bottom) for 3 days at 26-27C. The viral medium was then 
collected, and stored in dark boxes at 4C for several weeks, or at -80C for longer 
periods. The expression level of each cDNA was monitored by western blot at the end of 
each round infection using WCL from the infected cells. For large-scale protein 
purification, 4x107 cells were infected and maintained in flasks (50 mL final volume in 
250 flask) in an orbital shaker for 3-6 days at 27C, 120 rpm. Cells were then harvested 
by centrifugation and used to make protein lysates.      
 
2.5 Protein purification from Baculovirus system 
        To purify the recombinant proteins, recombinant baculoviruses were used to infect 
Sf21 cells. For complex purification, different baculoviruses were used to co-infect Sf21 
cells. After 3 to 5 days of infection, cells were harvested and resuspended in buffer C (50 
mM HEPES [pH 7.9], 5 mM MgCl2, 20% glycerol, 0.2% Triton X-100, 300 mM NaCl, 1 
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mM dithiothreitol [DTT], 1 mM phenylmethylsulfonyl fluoride [PMSF]) with a protease 
inhibitor cocktail (Roche). Then, the cells were homogenized by bead beating 3 times for 
30 s each time on ice. The supernatant was recovered by centrifuging at 15,000 rpm for 
10 min, and then the supernatant was further cleared by being centrifuged at 40,000 rpm 
for 1 h at 4°C. The supernatant was then incubated with the M2 anti-Flag–agarose 
(Sigma) or anti-HA matrix (Roche) equilibrated with washing buffer (10 mM HEPES [pH 
7.9], 1.5 mM MgCl2, 10 mM KCl, 0.1% Triton X-100, 300 mM NaCl, 1 mM DTT, 1 mM 
PMSF) with a protease inhibitor cocktail (Roche) overnight at 4°C. After being washed 
with washing buffer 3 times for 10 min each time, bound proteins were eluted with the 
Flag peptide (0.2 mg/ml) or HA peptide (0.4 mg/ml), respectively, for 2 to 4 h at 4°C or 
room temperature (RT) in elution base buffer (10 mM HEPES [pH 7.9], 100 mM NaCl, 
1.5 mM MgCl2, 0.05% Triton X-100, 0.2 mM EDTA, 10% glycerol, 1 mM DTT, 1 mM 
PMSF) (Lan et al., 2015). The eluted DUBm complexes were further purified through a 
gel filtration Superdex 200 column (GE Healthcare). 
 
2.6 Gel filtration  
        The eluted complexes were loaded onto a Superdex 200 column equilibrated in 
elution base buffer. The column was eluted with 1.5 column volumes of buffer, and 40 
fractions (each faction was 0.5 ml) were collected. Each fraction was concentrated to 30 
μl by Amicon Ultra centrifugal filters (Millipore) and analyzed using Western blotting with 
anti-HA and anti-Flag antibodies. All these processes were performed at 4°C 
(Kuzmichev et al., 2002). 
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2.7 In vitro deubiquitination assay 
        Total histones were prepared from HEK293T cells using a histone purification 
minikit (Active Motif). Free histones or nucleosomes (Epicypher) were incubated with 
purified recombinant proteins or complexes in DUB buffer (100 mM Tris-HCl, pH 8.0, 5% 
glycerol, 1 mM EDTA, 3 mM DTT) for 2 h or the times specified below at 37°C as 
described previously (Lang et al., 2011). SDS loading buffer was added to stop the 
reaction, and then Western blotting was performed to analyze the products of the 
reaction using specific antibodies. For in vitro assays using ubiquitin vinyl sulfone (Ub-
VS; Boston Biochem), the purified complexes were incubated with 1 μM or 5 μM Ub-VS 
in a reaction buffer (100 mM Tris-HCl, pH 8.0, 5% glycerol, 100 mM KCl, 3 mM DTT) for 
the times specified below at RT. Laemmli blue was added to stop the reactions, and then 
the reaction products were analyzed by immunoblotting. For reaction with ubiquitin–7-
amido-4-methylcoumarin (Ub-AMC; Boston Biochem), the purified complexes were 
incubated in DUB buffer (50 mM HEPES, pH 7.9, 0.5 mM EDTA, 0.1 M NaCl, 1 mM 
DTT, 0.1 mg/ml bovine serum albumin) on ice for 30 min and then at RT for 5 min. 
Reactions were initiated by adding 0.5 μM ubiquitin-AMC in DUB buffer. The reactions 
were monitored continuously for 15 min by determination of the fluorescence at 25°C 
(excitation λ, 360 nm; emission λ, 528 nm; Biotek Synergy 2 apparatus) as described 
previously (Yao et al., 2008). 
 
2.8 Preparation of cell lysates  
 
        Whole-cell extracts (WCEs) were prepared using radioimmunoprecipitation assay 
(RIPA) buffer or buffer C. The supernatants and pellets of WCEs from Sf21 cells or 
human astrocytes were separated after centrifuging at 15,000 rpm for 20 min at 4°C. 
Laemmli buffer was added to dissolve these pellets at 95°C for 5 to 10 min. Both the 
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supernatant and pellet fractions of whole-cell lysates were analyzed by Western blotting 
with the indicated antibodies. Or cell lysates were then sonicated for 10 min (30 sec on; 
30 sec off) using Biorupter Twin (Diagenode, UCD-400) and then centrifuged at 15000 
rpm for 20 min at 4°C. The clear supernatants were used as whole cell lysates (WCL) for 
Western blotting. 
 
2.9 Immunoprecipitation (IP) 
        1-2 mg of whole cell lysate or nuclear extract and 3-5 µg antibodies were used for 
each IP. Specific antibodies and normal rabbit (or normal mouse) IgG were added to the 
protein lysates and incubated overnight on a rocking platform at 4 °C. 40-50 µL (50% 
slurry) of pre-washed (by wash buffer 150 - 10 mM Tris-HCl pH 7.9, 10-20% glycerol, 
150 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 
protease inhibitors)) protein–G agarose beads (Millipore cat. # 16-266) were added to 
each sample and incubated for another 2 hours on a rocking platform at 4 °C. Beads 
were then collected by centrifugation for 1 min at 1000 rpm at 4 °C. Precipitated 
complexes were washed by wash buffer 150 and incubate on a rocking platform for 10 
min at 4 °C. Repeated once using wash 350 (10 mM Tris-HCl pH 7.9, 10-20% glycerol, 
350 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 
protease inhibitors) and 2 more times with wash buffer 150. Washed beads were then 
harvested by centrifugation, mixed with an equal volume of 1.5x SDS sample buffer and 
boiling for 10 min at 95C (heating block). Boiled beads were then removed by 
centrifugation at 15000 rpm, 1 min and the supernatants (usually 1/3) were used for 
western blot. For FLAG or HA tagged proteins, anti-FLAG (M2) (Sigma cat. #A2220), or 
anti-HA (Roche cat. #11815016001) beads were used. These IPs beads were washed 
and boiled in the same way as protein-G beads. FLAG and/or HA precipitated 
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complexes were eluted in wash 150 buffer containing 200 µg/mL 1x FLAG peptide 
(Sigma cat. # F3290) or 400  µg/mL HA peptide (Roche cat. #11666975001) for 2-4 
hours on a rocking platform at 4C or RT.  
 
2.10 Western blot analyses 
        20-30 µg of WCL or 1/3 of IP elutes were resolved on 4-12% NuPAGE gels (Life 
Technologies cat. # NW04122BOX). Proteins were transferred to 0.2 µm nitrocellulose 
membrane in Tris-Glycine buffer containing 10% Methanol for 75 min at a constant 100 
volts at 4 C after electrophoresis in SDS-PAGE, transferred nitrocellulose membrane 
was then blocked in 5% non-fat milk in TBS-T for 1 hour on an orbital shaker at RT and 
incubated with primary antibodies overnight on a rocking platform at 4°C. After washes 
in TBS-T 3x10 min, membranes were incubated with secondary-horseradish peroxidase 
(HRP) conjugated antibodies (GE Healthcare, Cat. # NA934V for Rabbit, NA931V for 
Mouse) for 1 hour on an orbital shaker at RT. Membranes were incubated with ECL 
Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences, RPN2232) for 
5 min and exposed after washes in TBS-T 3x(5-10) min. 
 
2.11 Nuclear extract preparation, affinity purification for gel filtration, 
deubiquitination assay or MudPIT analysis 
        Sample preparations for MudPIT analysis were performed as previously described 
(Atanassov et al., 2016). 293T cells stably expressing pINTO-N-FH-hUSP44, pINTO-N-
FH-hCETN2, pINTO-N-FH-hTBL1X or empty vector respectively were cultured in 
DMEM-H complete medium containing 100 µg/ml Zeocin. Cells were cultured in 15 cm 
plastic dishes (TPP cat. # 93150) at 37C and 5% CO2. (30-40) X15 cm dishes of ~80% 
confluent cells were used for each purification.  
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        Cells were harvested by trypsinization, washed twice in ice cold PBS containing 
protease inhibitors (Sigma cat. # P8340) and pelleted by centrifugation for 5 min at 200g 
at 4 C after each wash. Cell pellets were unpacked by flicking the tubes several times 
and resuspended in 10 pellet volumes of ice-cold hypotonic buffer (buffer A) (10 mM 
HEPES pH 7.5, 1.5 mM MgCl2, 10 mM KCl, protease inhibitors, 1 mM DTT, 1 mM PMSF) 
and cell suspensions were incubated on ice for 20 min. The swollen cells was moved to 
a glass homogenizer (7 mL Wheaton) and homogenized with 10 strokes by loose pestle. 
The homogenized cell suspension was collected in a fresh 50 mL Falcon tube and 
incubated on ice for another 20 min, nuclei were harvested by centrifugation at 500g for 
7 min at 4C. The supernatant (cytoplasmic fraction) was carefully removed and nuclei 
were then lysed in 5 pellet volumes of buffer C (20 mM Tris-HCl pH 7.9, 20% glycerol, 
420 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 
protease inhibitors) and lysates incubated on ice for 30 min. Lysed nuclei were then 
moved to a glass homogenizer and homogenized with 15 strokes by a tight pestle. 
Homogenates were collected in fresh 50 mL falcon tubes and an equal volume of ice-
cold buffer A (hypotonic buffer) containing DTT, PMSF and protease inhibitors. For pre-
clearing, lysates were centrifuged at 5,000g for 15 min at 4°C. The supernatants were 
then moved to ice-cold ultra centrifuge tubes, balanced, and centrifuged for 1.5 hours at 
45000 rpm at 4C using a Beckman 50.2Ti rotor. After this centrifugation, the clear 
supernatants were moved to new Falcon tubes (without touching any pellets or clouds) 
and labeled as Nuclear Extract (NE). A small fraction was used as an input after 
measuring the protein concentration by Bradford assays (Bio-Rad, Cat. # 500-0006). 
        An equal amount of total protein for all samples were moved to 50 mL Falcon tubes 
and 200 L of anti-FLAG (M2) beads (Sigma Cat. # A2220), pre-washed in wash buffer 
150 (10 mM Tris-HCl pH 7.9, 20% glycerol, 150 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 
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0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, protease inhibitors) were added to each 
tube, and then incubated for 4 hours or overnight on a rocking platform at 4°C.  After 
incubation, the beads were spinned down at 1000 rmp, 1 min at 4 C and then washed 
in wash buffer 150 1x10 min; wash buffer 350 (10 mM Tris-HCl pH 7.9, 10-20% glycerol, 
350 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 
protease inhibitors) 1x10 min and wash buffer 150 2x10 min on a rocking platform at 
4°C.  
        Precipitated complexes were eluted by incubating the beads in 2-5 bed volumes of 
wash buffer 150 containing 200 µg/mL 1xFLAG peptide (Sigma cat. # F3290) for 30 min 
on a rocking platform at 4°C. Eluates were collected in 1.5 or 2 mL Falcon tubes and the 
elution was repeated one more time using the same volumes and conditions. 80-100 L 
of pre-washed anti-HA beads (Roche cat. # 11815016001) were added to the FLAG 
eluates and mixtures were then incubated overnight on a rocking platform at 4°C. The 
beads were washed the same way as after the first IP. Precipitated complexes were 
eluted by 5 bed volumes of 100 mM glycine (pH 2.0) for 15 min on a rocking platform at 
4°C or by 2 bed volumes of wash buffer 150 containing 400 µg/mL HA peptide (Roche 
cat. #11666975001) for 2-4 hours on a rocking platform at RT. The beads were removed 
using chromatography columns (Bio-Rad Poly-Prep Cat. # 7311550). The eluates (two 
time elutions) by HA peptide were collected and concentrated down to ~25-45 L 
volume using centricons (Amicon Ultra, Millipore Cat. # UFC 501024 10K cut size) and 
then used for silver stain or western blots and gel filtration or DUB assay. For MudPIT 
analysis, the eluates by glycine (pH 2.0) were collected and neutralized by 1/10 eluate 
volumes of 1M Tris-HCl (pH 9.0). These elutes were then treated with Benzoase (Sigma 
cat. # E8263-5KU) 0.1U/tube on 37C for 30 min. The volume of the elutes was brought 
to 400 L by 100 mM Tris-HCl pH 8.5 and precipitated immediately by adding 100 L of 
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ice-cold trichloroacetic acid (TCA) (Sigma) (final concentration 20% w/v). Elutes-TCA 
mixtures were incubated for precipitation at 4C overnight. After the incubation, proteins 
were precipitated by centrifugation at 15,000 rpm for 30 min at 4C followed by 2 
immediate centrifugations at 15,000 rpm for 10 min at 4C. Pellets were then washed 
twice with ice-cold acetone (carefully remove acetone), air-dried in a fume hood and 
submitted for MudPIT analysis.    
 
2.12 In vitro binding assay 
        Recombinant HA-USP22 was incubated with recombinant Flag–ATXN7-24Q NT, 
Flag-ATXN7L3, or Flag-ENY2 at 16°C for 1 h. Then, the mixture was incubated with anti-
Flag–agarose overnight at 4°C (Yao et al., 2006). After being washed 3 times with 
washing buffer, bound proteins were eluted with Flag peptide (0.2 mg/ml) (Sigma, cat. # 
F3290). The input and eluate were analyzed by immunoblotting with anti-Flag and anti-
HA antibodies. 
 
2.13 Histone purification from ATXN7 Wild-type and mutant adult mouse 
cerebellums 
        Atxn7100Q alleles carried naturally occurring contracted mutations of the coding 
sequence for the 266-Q tract in Atxn7 obtained when maintaining the Atxn7266Q/5Q mouse 
line (Yoo et al., 2003). Cerebellums from mice with all three different genotypes were 
collected and snap-frozen. Total histones from the cerebellums were prepared using a 
histone purification minikit (Active Motif). Laemmli buffer was added, and the lysates 
were analyzed by Western blotting. All procedures that involved animal handling were 
performed in accordance with the approved IACUC protocols at the M. D. Anderson 
Cancer Center. 
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2.14 Immunofluorescence microscopy 
        Astrocytes were cultured on Geltrex lactate dehydrogenase-elevating virus-free, 
reduced growth factor basement membrane matrix (Life Technologies)-coated glass 
coverslips in 12-well plates for 24 to 48 h and then fixed with 3% formaldehyde, washed 
in phosphate-buffered saline (PBS), blocked with 10% fetal calf serum in PBS, and 
stained using primary antibodies (Sigma) and then secondary antibodies (Life 
Technologies). Nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole) in 
Vectashield mounting medium (Vector). Glass microslides with coverslips were allowed 
to set overnight to dry before coverslips were sealed with fingernail polish. Images were 
obtained using a laser scanning spectral confocal microscope (Leica STP6000). 
 
2.15 Transfection and lentiviral infection 
        60%-70% confluent 293T cells were transfected in Opti-MEM® I (Life Technologies) 
using Lipofectamine® 2000 (Life Technologies cat. # 11668019) following 
manufacturer’s instructions. The medium was changed to complete DMEM-H after Six to 
eight hours transfection. For lentiviral medium production, 293T cells were co-
transfected with lentiviral (the shRNA expressing pGIPZ) and psPAX.2 and pMD2.G 
(Addgene). After 72 hours transfection, the DMEM-H medium containing the lentiviral 
particles were collected, filtered through 0.45 µm filters and used for infection. For cells 
infection, the lentiviral medium was diluted 1:2 with the culture medium containing 4-8 
g/ml polybrene (Sigma, Cat. # H9268), infecting for 24-48 hours.  
 
2.16 Stable cell lines generation 
        293T cells stably expressing FLAG and HA-tagged hUSP44, hCETN2, or hTBL1X, 
were generated after transfection of 293T cells with pINTO-N-FH-hUSP44, pINTO-N-FH-
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hCETN2, pINTO-N-FH-hTBL1X or pINTO-N-FH empty vector and subsequent selection 
in DMEM-H complete medium containing 300 µg/ml ZeocinTM (Life Technologies cat. # 
R25001) for 2-3 weeks. The same method was used to generate 293T-Rex-luciferase 
cells stably expressing pINTO-N-GAL4-hTBL1X, pINTO-N-GAL4-hTBL1XR1 or pINTO-
N-GAL4 empty vector upon doxycycline induction. Stable 293T cell lines were 
maintained in medium containing 150 µg/ml Zeocin. Stable 293T-Rex-luciferase cells 
were maintained in medium containing 150 µg/ml Zeocin, 10 µg/ml blasticidin, and 
400 µg/ml G418. Cells stably expressing pGIPZ shRNAs were generated by infecting 
cells with the indicated viral medium and selected with 3 µg/mL Puromycin (Calbiochem 
cat. # 540222) for 48 hours and maintained in a medium containing 2 µg/mL Puromycin. 
 
 
2.17 Subcellular fractionation 
        Subcellular fractionations were performed as previously described (Mendez and 
Stillman, 2000). Briefly, 1 x107 Cells were lysed in 200 µl Buffer A (10 mM HEPES, pH 
7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 0.1% Triton X-100, 1 mM 
DTT, 1 mM PMSF, protease inhibitor). Lysed cells were separated nuclei from a crude 
cytoplasmic fraction (S1), which was further clarified by high-speed centrifugation. The 
supernatant was marked as the cytoplasmic fraction (S2). Nuclei were washed twice in 
Buffer A and then lysed in 100 µl Buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 1 
mM PMSF, protease inhibitor) to separate insoluble chromatin in the pellet (P3) from 
soluble nuclear protein in the supernatant (S3). P3 was washed once in Buffer B and 
resuspended in 200ul of 2X SDS loading buffer, boiled for 10min, and sonicated for 15 
sec 25% amplitude using EpiShear Probe Sonicator (Active Motif, Model CL-18). S2, S3 
and P3 were used for western blot analysis. 
 
27 
2.18 Quantitative RT-PCR analysis 
        Equal number of 293T cells or MDA-MB-231 cells expressing either non-targeting 
shRNA or shRNA targeting USP44 were seeded in 60 mm dishes. Cells were harvested 
after 24 hours and Total RNA was isolated using an RNeasy purification kit (Qiagen cat# 
74134) following the manufacturer’s instructions. 25-50 ng of total RNA was used as a 
template in each RT-qPCR reaction. The RT-qPCRs were performed using a 7500 Fast 
Real-Time PCR System (Applied Biosystems) and the Power SYBR Green RNA-to-CT 1 
step kit (Applied Biosystems cat.# 4389986). GAPDH was used as an internal control. 
Three technical replicates were used for each target per reaction. 
 
2.19 ChIP-qPCR 
        Chromatin IP (ChIP) was performed as described (Atanassov et al., 2016). Equal 
number (10x106) of 293T-Rex-luciferase cells stably expressing GAL4-TBL1XR1 upon 
doxycycline induction were seeded in 10 cm dishes and then transfected with pCAG-
USP44-C-FH. 24 hours post transfection, cells were treated with 100 ng/ml doxycycline. 
After 24 hours doxycycline induction, cells were cross-linked by adding Formaldehyde to 
the cultural medium (1% final concentration) and then incubated on an orbital shaker for 
10-15 min at RT. The cross-linking reaction was stopped by adding glycine to the 
medium (final concentration 125mM) and incubation for 5 min. The medium was then 
aspirated and cells washed 2 times with ice-cold PBS containing protease inhibitors 
(PBS+PI). Cells were scraped into 4 ml ice cold PBS+PI, moved to 15 ml Falcon tubes 
and pelleted by centrifugation for 8 min at 3500g at 4C. The cell pellets were 
resuspended in 2 ml PBS+PI, moved to two 1.5 ml tubes 1 ml in each and centrifuged 
again for 3 min at 2500g at 4C. After aspiration of the supernatant, the cell pellets were 
resuspended in 1 ml of cell lysis buffer +PI and incubated on ice for 10 min. Tubes were 
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flipped every 3-4 minutes by hand to keep the cells in suspension. After this incubation, 
cells were pelleted by centrifugation at 2500g for 5 min and the supernatants removed. 
Each pellet was then resuspended in 300µL of nuclei lysis buffer+PI, moved to 1.5 ml 
TPX tubes (Diagenode cat# C30010010-1000) and incubated on ice for 5 min. Tubes 
were then assembled onto a Bioruptor sample rotor (Bioruptor Plus sonication device) 
and sonicated for 50 cycles (30sec on/30sec off) with 5 min interval between every 10 
cycles with the temperature of the water in the sonication chamber kept between 4C 
and 5C. After the sonication, samples were centrifuged at 15000 rpm for 10 min at 4C 
and supernatants carefully transferred to new 1.5 ml tubes. At this point, 5µL from each 
sample was used to check the DNA fragment size and concentration after reversion of 
the cross-links, following RNase treatment and purification of the DNA using a PCR 
purification kit (Qiagen). Equal amounts of chromatin (30 µg) was used for each ChIP 
reaction. The volume of the sonicated chromatin in each sample was justified with nuclei 
lysis buffer, and then diluted 10 times with ChIP dilution buffer (usually 2 mL final 
volume). The diluted chromatins were then pre-cleared by BSA-blocked protein-G 
agarose beads and incubating for 30 min using 360 rotor at 4C (30 µl per antibody). 
After the pre-clearing step, the beads were spin down at 1000 rpm, 1 min at 4 C and the 
clear supernatants were moved to new tubes, and 100µL (5%) were removed as an 
input (the inputs were kept at -20 C until ready to be processed together with the ChIP 
reactions). Indicated antibodies (2-5 µg) or anti-HA beads were added to each tube and 
incubated on a 360 rotor overnight at 4C. After this incubation, 50µL BSA-blocked 
protein–G agarose beads were added to each ChIP reaction, and mixtures were 
incubated on a 360 rotor for 1-2 hours at 4C. After this incubation, beads were washed 
as follows (5 min on a rocking platform at 4 C at each step): Low salt wash buffer 
(20mM Tric-Cl pH 8.0, 150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS) High salt 
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wash buffer (20mM Tris-Cl pH 8.0, 500mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% 
SDS), LiCl wash buffer (20 mM Tris-Cl pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% NP-40, 
1% Sodium deoxycholate), TE buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA). Beads were 
harvested by centrifugation at 1000 rpm, 1min and the supernatants were removed after 
each wash. Precipitated chromatin was eluted using 50µL of elution buffer (50 mM 
NaHCO3, 1% SDS, freshly made) to each tube and incubating for 15 min at room 
temperature, flicking the tubes every 2-3 min to keep the beads in suspension. After this 
incubation, the beads were spin down, and the clear elutes were moved to new tubes. 
The elution procedure was repeated one more time for a total of 100µL eluate for each 
ChIP reaction. For reversing the cross-links, 8 µl 4 M NaCl was added to each sample to 
final concentration 300 mM, and samples were incubated at 65C in hybridization oven 
overnight. The volume of the inputs collected above was adjusted to 100µL with ChIP 
elution buffer, and these samples were processed in the same way, together with the 
ChIP reactions. After this incubation, 1µL of DNase free, RNase A (10mg/ml) (boiled for 
10 min before use) was added to each sample and the samples were incubated at 37C 
for 1 hour. The DNA in each sample was purified using a PCR purification kit (Qiagen, 
cat# 28106) and eluted in 50 µl (twice, 25 µL each time) nuclease-free water (Ambion, 
cat# AM9937). 1-2 µl eluted DNA of each antibody was used as template for qPCR with 
specific primers. 5% input was diluted to 1% with nuclease-free water and then use 1-2 
µl for qPCR. The rest of eluted DNAs were stored at -20 C. 
 
2.20 Luciferase activity assay 
        Luciferase activity assay was performed as previously described (Gao et al., 2014). 
with modifications. Briefly, 293T-REx-luciferase cells (Vaquero et al., 2004) stably 
integrated with pINTO-GAL4 empty vector or with inserts of interest were treated 
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with100 ng/ml doxycycline. After 24 hours doxycycline induction, cells were lysed in 
passive lysis buffer and shaking for 15 min at RT. The cell lysate was centrifuged at 
15000 rpm for 10 min and the protein concentration of the resulting supernatant was 
determined by Bradford assay. 10-25 µg of the supernatant was used for luciferase 
activity assay with luciferase assay substrate (Promega, cat# E1500) using GloMax-96 
Microplate Luminometer (Promega). 
 
2.21 Transwell invasion assay 
        Invasion assay was performed according to the manufacturer’ s instructions 
(Corning, cat# 354480). Briefly, rehydrated Matrigel invasion chambers were placed in 
24-well plates with normal culture medium. 50,000 of MDA-MB-231 cells suspended in 
DMEM containing 0.1% BSA were seeded on the upper layer of the chambers. After 48 
hours incubation at 37°C with 5% CO2, the membranes at the bottom of chambers were 
fixed with methanol for 3 min and stained with 0.5% crystal violet for 5-10 min. Then the 
cells above the membranes were removed using cotton swabs. Membranes were dried 
and cells attached below the membranes were imaged using microscope (ZEISS, 
Axiovert 40 CFL). 
 
2.22 Mice 
Mouse sperm harboring Usp22FloxFrt allele were obtained from the Knock Out Mouse 
Project (KOMP) and then sent to MD Anderson Cancer Center Genetically Engineered 
Mouse Facility for in vitro fertilization. Rosa-Flpase mice (stock no: 009086), Pcp2-Cre 
mice (stock no: 004146) and hGFAP-Cre mice (stock no: 004600) were purchased from 
the Jackson Laboratory. Mice were housed with same sex littermates and had free 
access to lab chow and water after weaning. Mice were maintained on a 12-h light/dark 
31 
cycle (lights on at 06:00). The laboratory temperature remained at 21 ± 1 °C. All 
behavioural experiments were started at 09:00 ± 1 h and performed under protocols 
approved by the M. D. Anderson Cancer Center IACUC and in accordance with NIH 
Principles of Laboratory Animal Care guidelines. 
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Oligo Name Sequence (5’-3’) 
HA-USP22-Mlu I-F CGACGCGTCGGTAGCTTGGGGCCACCATGTACCCATACGATGTTCCAGAT 
TACGCTGTGTCCCGGCCAGAGCC 
V5-USP22-Mlu I-F CGACGCGTCGGTAGCTTGGGGCCACCATGGGTAAGCCTATCCCTAAC 
CCTCTCCTCGGTCTCGATTCTACG GTG TCC CGG CCA GAG CC 
USP22-Nde I-R GGAATTCCATATGGAATTCCCTACTCGTATTCCAGGAACTGTTTG  
Flag-ATXN7L3-Mlu I-F CGAACGCGTCGGTAGCTTGGGGCCACCATGGATTACAAG GATGACGAC 
GATAAGTCGCGAATG AAAATGGAGGAAATGTCTTTGTCTG 
V5-ATXN7L3-Mlu I-F CGACGCGTCGGTAGCTTGGGGCCACCATGGGTAAGCCTATCCCTAACC 
CTCTCCTCGGTCTCGATTCTACGAAAATGGAGGAAATGTCTTTGTCTG 
ATXN7L3-Nde I-R GGAATTC CATATG GAATTCC TCAGTTGATGTCATCATAGATGCTGGG 
Flag-ENY2-Mlu I-F CGAACGCGTCGGTAGCTTGGGGCCACCATGGATTACAAGGATGAC 
GACGATAAGTCGCGAATGGTGGTTAGCAAGATGAACAAAGATG 
V5-ENY2-Mlu I-F CGACGCGTCGGTAGCTTGGGGCCACCATGGGTAAGCCTATCCCTAACC 
CTCTCCTCGGTCTCGATTCTACG GTGGTTAGCAAGATGAACAAAGATG  
ENY2-Nde I-R GGAATTCCATATGGAATTCCTTAAAGGCTGGCATGCTGAGCAAG 
 
Table 3: Primers used for PCR 
 
 
 
 
 
Oligo Name Sequence (5’-3’) 
RT-qPCR Primers  
qhUSP44-Fwd-Exon1 GGGGAAAGACTGATTTTGAGG 
qhUSP44-Rev-Exon2 CATGTTTGCACGTATCCATTG 
qhUSP44-Fwd-Exon4 CCAGTTGTACTCACAGAAGCCC 
qhUSP44-Rev-Exon5 CCTGAATCGTTTGAGGTGCAG 
hGAPDH-Fwd ACCCACTCCTCCACCTTTGA 
hGAPDH- Rev CTGTTGCTGTAGCCAAATTCGT 
ChIP-qPCR Primers  
GAL4-Fwd CACCGAGCGACCCTGGATAAGC 
GAL4-Rev GCTTCTGCCAACCGAACGGAC 
 
Table 4: Primers used for RT-qPCR and ChIP-qPCR 
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Chapter 3: PolyQ expansions in ATXN7 affect solubility but not activity of the 
SAGA deubiquitinating module 
 
Contents of this chapter are based on Lan, X*., Koutelou, E*., Schibler, A.C., Chen, 
Y.C., Grant, P.A., and Dent, S.Y. (2015). Poly(Q) expansions in ATXN7 affect solubility 
but not activity of the SAGA deubiquitinating module. Mol Cell Biol 35, 1777-1787. (* 
Equal contribution authors) 
According to Mol Cell Biololgy, the author retains the ownership of copyright to 
reproduce the contribution or extracts from the original article. 
  
 
3.1 Solubility of ATXN7 polyQ is increased by incorporation into the DUBm 
        ATXN7 is required for tethering of the DUBm to the SAGA complex (Figure 5A), 
and the N-terminal zinc finger domain in ATXN7 is necessary and sufficient for the 
assembly and activation of the DUBm (Kohler et al., 2008; Lang et al., 2011). The N-
terminal part of the yeast ATXN7 homolog (Sgf73) has been used previously for 
biochemical and structural analysis of the DUBm, but the yeast protein lacks N-terminal 
sequences present in ATXN7 where polyQ expansions occur in SCA7 disease (Figure 
5B). To determine the effects of polyQ expansion on ATXN7 functions, I tested the 
assembly and enzymatic activity of an in vitro reconstituted recombinant mammalian 
DUBm.  
        I purified full length USP22, ATXN7L3, ENY2 proteins along with two forms of the 
ATXN7 N-terminal domain containing either 24Qs (ATXN7-24Q NT (WT) or 92Qs 
(ATXN7-92Q NT (mutant) from insect cells. All of the DUBm components except for 
ATXN7-92Q NT were expressed efficiently as individual recombinant proteins in 
baculovirus and were readily purified using anti-FLAG (for ATXN7, ENY2, and 
ATXN7L3) or anti-HA (for USP22) immunoprecipitation (Figure 5C). Expression of 
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ATXN7-92Q NT was undetectable (Figure 5C, lane 5), so we initially focused on defining 
interactions of ATXN7-24Q NT with other DUBm components.  Previous reports 
indicated that USP22 interacted with ATXN7L3 but not ENY2, as detected by 
immunoprecipitation after co-expression of USP22 and ATXN7L3 or USP22 and ENY2 
in insect cells, respectively (Zhao et al., 2008). I found that USP22 directly interacted 
with ATXN7L3, as well as with ATXN7-24Q NT, but not with ENY2, using in vitro binding 
assays after mixing individually purified recombinant DUBm subunits (Figure 6). These 
results suggest ENY2 is incorporated into the DUBm through interactions with ATXN7L3 
and/or ATXN7, which in turn interact with USP22. 
        The apparent lack of expression of ATXN7-92Q NT could reflect a defect in cDNA 
transcription, a defect in translation of the recombinant protein, a defect in the solubility 
of the protein, or a problem with protein stability.  ATXN7-polyQ proteins form 
aggregates in mammalian cells (McCullough et al., 2012), so I re-examined our 
baculovirus supernatant and pellet fractions for expression of the ATXN7-24Q NT and 
ATXN7-92Q NT proteins. I found that ATXN7-24Q NT was soluble, as the main fraction 
of the protein was detected in the supernatant (Figure 5D, lanes 3 and 4), whereas the 
majority of ATXN7-92Q NT was insoluble and was detected mainly in the pellet (Figure 
5D, lanes 5 and 6). Importantly, solubility of ATXN7-92Q NT was greatly increased upon 
co-expression with other DUBm components, as decreased levels of the insoluble 
protein were observed, with a corresponding increase in levels of the soluble form, in 
cellular extracts from cells expressing all four subunits (Figure 5D, lanes 7 and 8). I 
successfully isolated reconstituted DUBm complexes containing ATXN7-24Q NT or 
ATXN7-92Q NT using single affinity purification using HA agarose beads, and I verified 
the presence of all four subunits both by colloidal staining (Figure 5E) and by 
immunoblotting with anti-HA and anti-FLAG antibodies against the tagged subunits 
(Figure 5F). These results indicate that polyQ expanded forms of ATXN7 do not prevent 
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interactions with other DUB components, and that solubility and proper folding of 
ATXN7-92Q NT, which is prone to aggregate, were enhanced after the incorporation into 
the DUB complex. 
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Figure 5: Reconstitution of the mammalian DUBm.  
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Figure 5: Reconstitution of the mammalian DUBm. 
(A) Schematic of the mammalian SAGA DUBm. (B) Schematic representation of ATXN7 
N-terminal fragments with 24 Q residues and 92 Q residues, where Q is glutamine. (C) 
Colloidal staining of DUBm subunits after elution with HA or Flag peptides from 
immunoaffinity agarose beads. The expression levels are similar for all the subunits 
analysed, with the exception of the expression level for ATXN7-92Q NT. #, purified 
DUBm subunits in each lane. (D) Expression of exogenous Flag-ATXN7 NT in WCEs 
from Sf21 insect cells after cellular fractionation at 3 days postinfection in order to 
assess the solubility of ATXN7-24Q NT and ATXN7-92Q NT. Lanes S, supernatant 
(soluble fraction); lanes P, pellet (insoluble fraction). Numbers on the left are molecular 
masses (in kilodaltons). (E) Colloidal staining of the reconstituted DUBm with ATXN7-
24Q NT or ATXN7-92Q NT after anti-HA (USP22) immunoprecipitation. (F) Immunoblot 
analysis of the reconstituted DUBm for which the results are presented in panel E. 
ATXN7-24Q NT or ATXN7-92Q NT, ATXN7L3, and ENY2 are all Flag tagged and are 
detected with anti-Flag antibody; HA-USP22 is detected with anti-HA antibody. “*” 
modified forms of ATXN7-24Q NT or ATXN7-92Q NT due to ubiquitination (data not 
shown). Lanes M (C and E), molecular mass markers; IB, immunoblot analysis; IP, 
immunoprecipitation analysis. 
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Figure 6: In vitro binding assay shows USP22 directly interacts with ATXN7 or 
ATXN7L3, but not with ENY2. 
Purified recombinant USP22 was incubated with recombinant ATXN7-24Q, ATXN7L3 or 
ENY2 in elution base buffer at 16 oC for 1 hr and precipitated with anti-FLAG agarose 
beads. After three washes with wash buffer, bound proteins were eluted with FLAG 
peptide and analyzed by immunoblotting with anti-HA and anti-FLAG antibodies. ‘‡’ 
Daggers denote degradation products of ATXN7L3 due to its incubation at 16 oC. USP22 
was tagged with HA; ATXN7-24Q NT, ATXN7L3 and ENY2 were tagged with a FLAG 
epitope. 
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3.2 ATXN7 enhances DUB activity in vitro 
        The enzymatic activity of the SAGA DUB module requires the ATXN7 homolog in 
yeast (Kohler et al., 2008), but it has recently been shown to be dispensable in the 
drosophila DUB module (Mohan et al., 2014). A study with the mammalian components 
found that USP22 is partially activated in vitro upon interaction with ATXN7L3 and 
ENY2, and that full activity required additional interactions with ATXN7 (Lang et al., 
2011), but those studies did not address the effects of polyQ expansions as their 
construct lacked the region that contains the polyQ repeats. I addressed the role of wild 
type and mutant ATXN7 in overall DUB assembly and activity in vitro. I first reconstituted 
subcomplexes by co-infecting various combinations of the three recombinant 
baculoviruses into Sf21 cells.  I then purified the subcomplexes by immunoprecipitation 
using the HA epitope on USP22, and we used the catalytically inactive USP22 C185S 
mutant as a negative control (Figure 7A).  I found that USP22 forms tripartite 
subcomplexes with ATXN7L3 and ENY2 (Figure 7B, lane 1, Figure 7C, lane 2), with 
ATXN7-24Q NT and ENY2 (Figure 7D, lane 1), or with ATXN7-24Q NT and ATXN7L3 
(Figure 7D, lane 2). I tried to reconstitute subcomplexes by co-infecting combinations of 
two recombinant proteins in order to test the stability of these pairwise interactions, but 
we found that the USP22-ATXN7-24Q subcomplex was the only stable two-component 
complex formed (Figure 7D, lane 4).  Although USP22 can interact with either ATXN7-
24Q or ATXN7L3, the formation of stable subcomplexes requires the presence of more 
than two subunits of the DUBm, indicating that these interactions impact not only the 
enzymatic activity of the DUBm, but also the stability of the complex. 
        I next characterized the DUB activity of these subcomplexes using core histones 
(isolated from human 293T cells), which include H2Bub (Figure 8A, lane 1), as 
substrates.  No H2Bub DUB activity was detected in the presence of USP22 alone 
(Figure 8A, lane 2) or with the USP22 C185S mutant (Figure 8A, lanes 3 and 5), as 
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expected. As previously reported, USP22 efficiently deubiquitinated H2Bub when in 
complex with ATXN7L3 and ENY2 within two hours of incubation (Figure 8B, lane 3), 
whereas DUBm subcomplexes that lacked ATXN7L3 or ENY2, did not (Figure 8B, lanes 
2, 4, 5 and 6).  These results are consistent with a recent report that the Drosophila 
SAGA DUBm is active without ATXN7 (Mohan et al., 2014). Importantly, a time course 
experiment reveals that ATXN7-24Q NT further stimulates the activity of the mammalian 
DUBm, as deubiquitination of both H2B (Figure 8C, compare lanes 5, 6, 7, and 8 to 
lanes 9, 10, 11 and 12) and H2A (Figure 8D, compare lanes 5, 6, 7 and 8 to lanes 9, 10, 
11 and 12) is significantly more efficient in the presence of ATXN7. Deubiquitination of 
H2A and H2B in mononucleosomes is also more efficient in the presence of ATXN7-24Q 
NT (Figure 8E, compare lanes 5, 6, 7 and 8 to lanes 9, 10, 11 and 12 and data not 
shown).  
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Figure 7:  Reconstitution of mammalian DUBm sub-complex. 
(A-D) Silver stainings of polyacrylamide gels displaying recombinant USP22 and 
different subcomplexes of DUBm eluted from HA agarose beads after USP22 affinity 
purifications to verify the expression of DUBm subunits and the purity of these 
recombinant proteins for control DUB assays. ‘*’ denotes degradation products of 
ATXN7L3 or USP22. ‘#’ on left of bands in (D) indicates the DUBm subunits purified in 
different combinations. USP22 WT or catalytic mutant was tagged with HA; ATXN7-24Q 
or 92Q NT, ATXN7L3 and ENY2 were tagged with FLAG. 
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        To further assess the stimulation of DUB activity by ATXN7-24Q NT, I used a 
fluorescent substrate, ubiquitin C-terminal 7-amido-4-methylcounmarin (Ub-AMC), which 
provides a more quantitative assay for ubiquitin C-terminal hydrolase activity (Case and 
Stein, 2006). I confirmed the requirement of ATXN7-24Q NT for robust Ub-AMC 
hydrolyzing activity, whereas the reconstituted DUBm without ATXN7-24Q NT showed 
only minimal activity (Figure 9A). Similarly, the DUBm without ATXN7L3 or ENY2 had no 
detectable activity on Ub-AMC (Figure 9B). To extend these observations, I assayed the 
enzymatic activity of the different DUBm subcomplexes using ubiquitin vinyl sulfone (Ub-
VS). Ub-VS is a DUB inhibitor, and it covalently attaches to the active site of the catalytic 
DUB subunit causing a shifted migration upon gel electrophoresis (Borodovsky et al., 
2001). Although some shift of USP22 alone was observed when using higher 
concentrations of Ub-VS (1M vs 5 M) (Figure 9C, compare lane 1 with Figure 9D lane 
1), both ATXN7L3 and ENY2 strongly promoted reactivity (Figure 9C-E), and this 
reactivity was further stimulated by ATXN7-24Q NT (Figure 9F). Altogether, these results 
demonstrate that ATXN7L3 and ENY2 are required for minimal activation of USP22, but 
ATXN7 significantly stimulates this enzymatic activity.   
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Figure 8: ATXN7-24Q NT promotes robust DUB activity of the DUBm in vitro. 
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Figure 8: ATXN7-24Q NT promotes robust DUB activity of the DUBm in vitro.  
(A) In vitro deubiquitination assays using core histones as the substrates were 
performed with USP22 alone (lanes 2 and 3), trimeric DUBm (no ATXN7-24Q NT; lane 
4), and tetrameric DUBm (with ATXN7-24Q NT, lanes 5 and 6). The USP22 C185S 
catalytically inactive mutant served as a negative control (lanes 3 and 5). The trimeric 
and tetrameric complexes had similar activities on ubiquitinated H2B after 2 h. (B) In 
vitro DUB assays using core histones were performed for different combinations of 
DUBm subunits coinfected in Sf21 insect cells, in order to test potential enzymatic 
activity. Similar amounts of USP22 in these complexes were incubated with core 
histones for 2 h. No activity was observed in any dimeric complex (lanes 5 and 6), and 
the only trimeric complex with obvious enzymatic activity contained USP22, ATXN7L3, 
and ENY2 (lane 3). (C and D) In vitro DUB assays using core histones were performed 
with USP22 alone (lanes 1 to 4), DUBm (no ATXN7-24Q NT; lanes 5 to 8), and DUBm 
(with ATXN7-24Q NT; lanes 9 to 12), and samples were collected for analysis at the 
indicated time points. H2A (D) and H2B (C) ubiquitination was monitored with antibodies 
specific for these modifications. In all assays (A to D), core histones were purified from 
HEK293T cells. (E) In vitro DUB assay for H2A of total mononucleosomes shows that 
ATXN7 promotes the DUB activity of DUBm. 
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Figure 9: Both ATXN7L3 and ENY2 are required for the activation of DUB activity 
of USP22 and ATXN7 further stimulates the DUB activity of DUBm.  
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Figure 9: Both ATXN7L3 and ENY2 are required for the activation of DUB activity 
of USP22 and ATXN7 further stimulates the DUB activity of DUBm.  
(A) Hydrolysis of ubiquitin-AMC (0.5 μM) alone or with similar amounts of recombinant 
USP22, DUBm (no ATXN7-24Q NT), and DUBm (with ATXN7-24Q NT). The release of 
AMC fluorescence was monitored by a spectrophotometer at 528 nm. The tetrameric 
DUBm with ATXN7-24Q NT showed the highest enzymatic activity. The USP22 WT or 
catalytic mutant was tagged with HA; ATXN7-24Q NT, ATXN7L3, and ENY2 were all 
tagged with Flag. (B) Ub-AMC hydrolysis assay using the indicated complexes. As a 
control, Ub-AMC was incubated with DUB buffer alone. USP22 WT or catalytic mutant 
was tagged by HA; ATXN7-24Q or 92Q NT, ATXN7L3 and ENY2 were tagged by Flag. 
C-F) Equal amounts of the different purified complexes were incubated with or without 
1uM or 5 uM ubiquitin vinyl sulfone (Ub-VS), a suicide substrate of deubiquitinases at 37 
oC for 2 hrs. This compound can form a covalent bond only with active form of USP22, 
which is characterized by a ~7 kDa shift of the enzyme using immunoblot analysis with 
anti-HA antibody. The stronger activity the deubiquitinase possesses, the more shift it 
shows. USP22 alone shows poor activity. Quantitation of the HA-USP22-Ub-VS was 
normalized by HA-USP22 using ImageJ program.  
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3.3 PolyQ ATXN7 does not impair the assembly or activity of the DUBm in vitro 
        Due to the decreased solubility of ATXN7-92Q NT, it was difficult to isolate this 
protein as part of the DUBm complex in vitro (Figure 5E, lane 2).  To determine whether 
I could increase ATXN7-92Q NT amounts to a more stoichiometric ratio in the complex, I 
first titrated increasing amounts of the ATXN7-92Q NT recombinant baculovirus relative 
to those expressing the other subunits, and then isolated the DUBm complex by 
immunoprecipitation using the HA epitope on USP22. I analyzed the isolated 
reconstituted DUBm complexes both by silver staining (Figure 10A) and by immunoblot 
using anti-HA and anti-FLAG antibodies against the tagged subunits (Figure 10B). 
Increasing amounts of ATXN7-92Q NT protein were detected after single step 
purification of USP22 associated proteins, but the silver stained gel indicated that this 
subunit was still present in sub-stoichiometric levels relative to other components, 
indicating ATXN7-92Q NT was incorporated into a minority of the isolated complexes. 
However, ATXN7-92Q NT greatly enhanced the activity of the DUBm, as showed by Ub-
AMC assays and in vitro DUB assay (Figure 10C-D), even when present at sub-
stoichiometric levels.  To better assess the effects of the polyQ expansions on DUBm, I 
next performed a double affinity purification using sequential anti-HA and anti-FLAG 
immunoprecipitations. The components of the purified DUBm complex were again 
monitored by electrophoresis (colloidal staining; Figure 11A) and by immunoblot with 
anti-HA and anti-FLAG antibodies (Figure 11B). The amounts of DUBm subunits 
incorporated into the complexes containing ATXN7-24Q NT and ATXN7-92 NT were 
present in  similar ratios (Figure 11B), so I performed Ub-AMC assays to directly 
compare their enzymatic activities I observed no difference between the ability of the two 
complexes to hydrolyze Ub-AMC (Figure 11C).  
        To further confirm these results, I repurified the DUBm using HA 
immunoprecipitation followed by gel filtration to remove free HA-USP22 as well as 
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partially formed complexes. Immunoblotting analysis of the column fractions indicated 
that the fully assembled DUB complex eluted with an apparent molecular weight of ~200 
kDa (Figure 11D-E). The differences in solubility of the two ATXN7 polyQ proteins did 
not directly affect the assembly of DUB module as, once incorporated, ATXN7-24Q NT 
and ATXN7-92Q NT were both associated with similar amounts of the other DUBm 
subunits (Figure 11F). In order to assay equivalent amounts of the reconstituted DUB 
module, I normalized amounts of ATXN7-24Q NT with ATXN7-92Q NT collected from 
fractions 23 and 24, as confirmed by western blot (Figure 11F), and then carried out 
DUB assays using core histones or mononucleosomes as substrates. Importantly, I 
again found that ATXN7-92Q NT stimulated DUB activity to the same degree as ATXN7-
24Q NT (Figure 11G-H). Our results demonstrate that a polyQ expansion in ATXN7 
equivalent to those found in SCA7 patients does not affect the enzymatic activity of the 
SAGA DUBm in vitro.  
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Figure 10: Increased incorporation of ATXN7-92Q into DUBm promotes DUBm 
activity.  
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Figure 10. Increased incorporation of ATXN7-92Q into DUBm promotes DUBm 
activity.  
(A) Silver staining of DUBm with increasing amounts of subunit ATXN7-92Q NT after 
anti-HA (USP22) precipitation. Similar titers of USP22, ATXN7L3, ENY2 baculoviruses 
and increasing titers of ATXN7-92Q NT baculovirus were used to co-infect Sf21 cells, 
respectively. After 4-6 days of infection, anti-HA affinity matrix was used to purify these 
complexes. Increasing amounts of ATXN7-92Q NT protein incorporated into the DUBm 
are detected. (B) Immunoblot analysis of the reconstituted DUBm  described in A, using 
anti-HA (USP22), anti-FLAG (ATXN7, ENY2, and ATNX7L3) and anti-ATXN7L3 
antibodies. A tetrameric complex with all four subunits in the presence of ATXN7-92Q 
NT is observed. Degradation fragments are labeled with ‘#’. “*” Asterisk denotes 
modified forms of ATXN7-92Q NT due to ubiquitination (data not shown). (C) 
Comparative Ub-AMC hydrolysis assays using the reconstituted DUBm complexes with 
increasing amounts of ATXN7-92Q NT show that the more ATXN7-92Q NT incorporated 
into the complex, the more robust the enzymatic activity of the reconstituted DUBm (I 
used 1x (low) and 3x (high) amounts for the comparison). (D) In vitro DUB assays using 
purified total histones as the substrate were performed with DUB modules containing 
increased amounts of subunit ATXN7-92Q NT after anti-HA (USP22) precipitation, and 
H2A ubiquitination levels were monitored with antibodies specific for this modification. 
H2A served as a loading control. 
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Figure 11: ATXN7-92Q NT is not defective in promoting DUBm activity.  
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Figure 11: ATXN7-92Q NT is not defective in promoting DUBm activity.  
(A) Purification of the recombinant DUBm using two sequential affinity precipitations with 
anti-HA– and anti-Flag–agarose beads, respectively. Comparison of the two purified 
DUBm complexes containing ATXN7-24Q NT or ATXN7-92Q NT with colloidal staining 
shows very similar ratios of the DUBm subunits. Lane M, molecular mass markers. (B) 
Immunoblot analysis (low and high exposures are shown) of the DUBm after double-
affinity purification (A) verifies the identities and the presence of similar amounts of 
DUBm components. The different subunits were detected with anti-HA and anti-Flag 
antibodies, as indicated. “*” modified forms of ATXN7-24Q NT or ATXN7-92Q NT due to 
ubiquitination (data not shown). (C) Comparative Ub-AMC hydrolysis assays using the 
reconstituted DUBm complexes with either ATXN7-24Q NT or ATXN7-92Q NT after the 
double-affinity purification confirm the very similar deubiquitinating activities between the 
two complexes. (D and E) Purification of reconstituted DUBm containing ATXN7-24Q NT 
(C) or ATXN7-92Q NT (D) by size exclusion chromatography using Superdex 200 gel 
filtration. Column fractions (numbers above the blots) were analyzed by immunoblotting 
with anti-HA (USP22) and anti-Flag (ATXN7, ATXN7L3, and ENY2) antibodies, and 
band positions for these components are as indicated. The elution profile of protein 
markers is indicated at the top of the blots. A complex containing all four subunits, 
including either ATXN7-24Q NT or ATXN7-92Q NT, is present in fractions 23 and 24 of 
both purifications and corresponds to the expected molecular mass for the DUBm. A 
darker exposure of the input lane for the ATXN7-92Q NT purification (labeled high) is 
provided to confirm the presence of all components in the starting material. ‡, 
degradation fragments. (F) Comparison of the integrity and stoichiometry of fraction 24 
of the gel filtration from panels D and E was performed by immunoblotting with anti-HA 
and anti-Flag antibodies. Note that the amounts of the different subunits between the 
two reconstituted DUBm complexes are very similar. *, modified form of ATXN7-24Q NT 
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or ATXN7-92Q NT due to ubiquitination (data not shown). (G and H) In vitro DUB assays 
using purified mononucleosomes as the substrate were performed with both DUB 
modules, and H2A and H2B ubiquitination levels were monitored with antibodies specific 
for these modifications. Both reconstituted complexes showed very similar enzymatic 
activities toward both ubiquitinated histone H2A and H2B incorporated into nucleosomes 
at the time points analyzed. H2A or H2B immunoblotting or Ponceau S staining served 
as a loading control. 
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3.4 ATXN7-92Q aggregates sequester DUBm components in vivo 
        Nuclear aggregation of polyQ proteins is a hallmark of CAG expansion disorders 
(Todd and Lim, 2013). Aggregates associated with ATXN7-polyQ mutant proteins also 
include transcriptional regulators, ubiquitin/proteasome proteins, cell death associated 
proteins, chaperones and protein partners (Lebre and Brice, 2003). Previous work 
indicates that expression of ATXN7-92Q, but not ATXN7-24Q, leads to formation of 
aggregates and that GCN5, the catalytic subunit of HAT module in SAGA, is 
sequestered into these aggregates in human astrocytes (McCullough et al., 2012). I 
reconfirmed aggregate formation in the presence of ATXN7-92Q (Figure 12A) and then 
asked whether other DUBm components were also present within the aggregates 
observed in astrocytes. Double immunofluorescence staining with anti-FLAG to detect 
ATXN7-92Q and anti-ATXN7L3 antibodies demonstrated that endogenous ATXN7L3 
was present in nuclear inclusions in astrocytes (n=86) containing ATXN7-92Q 
aggregates (Figure 12A, middle panel and data not shown).  Since the solubility of 
ATXN7-92Q was improved in baculovirus cells upon co-expression of other DUBm 
subunits (Figure 5D), I asked whether such co-expression would also increase solubility 
and decrease aggregation in mammalian cells. Indeed, immunoblot analyses of human 
astrocyte extracts showed that co-overexpression of ATXN7L3 and ENY2 promoted the 
solubility of ATXN7-92Q and greatly inhibited its aggregation (Fig.12B, compare lanes 3 
and 4). Increased solubility of ATXN7-92Q in transfected astrocytes was also indicated 
by immunofluorescence, as co-overexpression of ATXN7L3 and ENY2 clearly 
suppressed formation of ATXN7-92Q aggregates (Figure 12A, bottom panel). I further 
quantified this effect by counting cells showing no aggregates (N=0), 1 or 2 aggregates 
(N≤2), or more than 2 aggregates (N>2).  Co-overexpression of ATXN7L3 and ENY2 
greatly decreased the number of cells with more than 2 aggregates per nucleus (N>2, 
~10% vs ~40% when ATXN7-92Q is expressed alone) (Figure 12C). Consistent with 
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these results, co-localization of ATXN7L3 with nuclear inclusions also decreased upon 
co-overexpression of ATXN7L3 and ENY2 (Figure 12A and Figure 12D ~35% vs ~5%;  
n=86). Overexpression of USP22, ATXN7L3 or ENY2 alone with ATXN7-92Q did not 
cause any obvious decrease in aggregation of ATXN7-92Q (data not shown). These 
results indicate that aggregates caused by ATXN7-polyQ mutants may be cytotoxic due 
to sequestration of important DUBm components and that co-overexpression of 
ATXN7L3 and ENY2 may oppose this toxicity through suppressing aggregate formation.  
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Figure 12: Overexpression of ATXN7L3 and ENY2 prevents sequestration of 
ATXN7L3 into aggregates with ATXN7-92Q in vivo.   
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Figure 12: Overexpression of ATXN7L3 and ENY2 prevents sequestration of 
ATXN7L3 into aggregates with ATXN7-92Q in vivo.   
(A) Exogenous expression of ATXN7-92Q, but not that of ATXN7-24Q, causes 
aggregate formation in human astrocytes. ATXN7L3 colocalization with nuclear 
inclusions in ATXN7-92Q-expressing astrocytes was observed by immunofluorescence 
staining using anti-Flag and anti-ATXN7L3 antibodies. Co-overexpression of ATXN7L3 
and ENY2 reduces this colocalization by inhibiting ATXN7-92Q aggregation. Nuclei were 
stained with DAPI (blue). Bar, 10 μm. (B) Upon co-overexpression of ATXN7L3 and 
ENY2 with ATXN7-92Q, the amount of soluble ATXN7-92Q in the supernatant fraction 
increased, whereas the amount of SDS-insoluble ATXN7-92Q aggregates in the pellet 
(trapped in the stacking gel) dramatically decreased compared to the amount obtained 
with overexpression of ATXN7-92Q alone. ATXN7-24Q is highly soluble. Anti-β-actin 
immunoblotting served as a loading control. ATXN7-24Q and ATXN7-92Q were tagged 
with Flag. ATXN7L3 and ENY2 were tagged with a V5 epitope. (C) Quantification of 
astrocytes containing nuclear inclusions. One hundred cells from multiple fields were 
counted and then sorted by the number of nuclear inclusions per cell (N). Three 
independent experiments were performed, and a two-tailed Student t test was used for 
statistical analysis; error bars represent ±SDs. (D) Quantification of astrocytes with 
endogenous ATXN7L3 co-localization with nuclear inclusions. Three independent 
experiments were performed, and a two-tailed Student t test was used for statistical 
analysis; error bars represent SDs. 
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3.5 Increased solubility of ATXN7-92Q rescues DUB activity in vivo 
        Given that depletion of ATXN7L3 caused robust increases in global H2Bub levels 
(Lang et al., 2011), sequestration of ATXN7L3 into ATXN7-92Q aggregates might affect 
global H2Bub levels. Consistent with previous work (McCullough et al., 2012), which 
indicated that global H2Bub levels were increased in astrocytes overexpressing ATXN7-
92Q compared to those in wild type astrocytes, I found that H2Bub levels were 
increased in astrocytes upon over expression of ATXN7-92Q (Figure 13A). Interestingly, 
acetylation of H3 K9 and K14 was not altered in the ATXN7-92Q overexpressing cells, 
even though Gcn5 is also associated with aggregates in ATXN7 polyQ cells 
(McCullough et al., 2012).  Importantly, co-overexpression of ATXN7L3 and ENY2 
together with ATXN7-92Q opposed the increase in global H2Bub (Figure 13B, compare 
lane 2 to lane 4), suggesting that compromised DUB activity caused by aggregation of 
DUBm components can be rescued by co-overexpression of ATXN7L3 and ENY2. 
Together with our biochemical data that indicate ATXN7L3 and ENY2 are required to 
activate USP22 activity, these findings suggest that aggregates caused by ATXN7-polyQ 
mutant likely contribute to neuronal toxicity by impairing DUB activity through 
sequestering important DUBm components away from their substrates and that 
increased solubility of ATXN7 polyQ mutant by co-overexpression of DUBm components 
can counteract this toxicity. 
        Accumulation of ubiquitinated proteins is observed in SCA7 and other polyQ 
diseases in association with nuclear aggregation of the polyQ proteins, indicating that 
the polyQ expansions influence processing of ubiquitinated proteins in vivo (Ansorge et 
al., 2004; Cummings et al., 1998; Davies et al., 1998). To determine if sequestration of 
DUBm components influences H2Bub in a mouse model of SCA7 (Chen et al., 2012; 
Yoo et al., 2003), I extracted histones from the cerebellums of mice bearing one or two 
alleles of ATXN7-100Q, and compared H2Bub levels relative to histones extracted from 
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age matched wild type, ATXN7-5Q, mice. I found a slight increase in H2Bub levels in 
histones isolated from mice heterozygous for the expanded ATXN7 allele (ATXN7 
100Q/5Q), and an even greater increase in H2Bub levels in ATXN7-100Q homozygous 
mice (Figure 13C, lanes 2 and 3). These results further indicate that DUB activity is 
indeed impaired by the ATXN7 polyQ expansions in a SCA7 mouse model. 
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Figure 13: Solubility of ATXN7-92Q in vivo correlates with DUB activity. 
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Figure 13: Solubility of ATXN7-92Q in vivo correlates with DUB activity. 
(A) Core histones were purified from human astrocytes infected with empty vector (lanes 
1 to 3), ATXN7-24Q (lanes 4 to 6), or ATXN7-92Q (lanes 7 to 9) and were analyzed by 
electrophoresis of increasing sample amounts (1× to 3×), and the levels of H2Bub were 
monitored with antibodies specific for this modification. The levels of H2B ubiquitination 
increased in astrocytes expressing ATXN7-92Q, indicating impaired deubiquitination. 
Quantification of H2Bub levels was normalized to H2B levels using ImageJ software. (B) 
Cooverexpression of ATXN7L3 and ENY2 enhances global H2Bub deubiquitination in 
astrocytes expressing ATXN7-92Q, whereas H3K9/14ac levels are not altered. Different 
sample amounts (1× and 3×) were analyzed. H2B immunostaining or Ponceau S 
staining served as a loading control. (C) Core histones were purified from the 
cerebellums of 4-month-old mice bearing wild-type (5Q) or mutant (100Q) alleles of the 
ATXN7 gene. Both ATXN7100Q/100Q and ATXN7100Q/5Q mice exhibit SCA7 symptoms over 
time, but disease progression in ATXN7100Q/100Q mice was faster and more severe than 
that in ATXN7100Q/5Q mice. Immunoblot analysis was used to detect H2Bub levels with 
anti-H2Bub antibody. Samples from both ATXN7100Q/100Q and ATXN7100Q/5Q mice show 
increased H2B ubiquitination, with the effect being more severe in the samples from 
ATXN7100Q/100Q mice. H2Bub levels were normalized to H2B levels using ImageJ 
software. Representative results chosen from more than three independent experiments 
are shown. (D) Model of the contribution of ATXN7-poly(Q) to SCA7 disease in humans. 
In vitro, soluble DUBm with ATXN7-92Q exhibits DUB activity comparable to that of the 
DUBm with ATXN7-24Q. However, in vivo ATXN7-poly(Q) tends to form aggregates that 
sequester DUBm components away from their substrates. Incorporation into DUBm can 
help solubilize ATXN7-poly(Q) in vitro and in vivo, partially alleviating the formation of 
the poly(Q)-containing aggregates in astrocytes. Impaired DUB activity in the 
cerebellums of SCA7 patients expressing ATXN7-poly(Q) likely leads to increased global 
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H2Bub levels, as well as the deregulation of other DUBm substrates, contributing to 
SCA7 disease. Model in figure 13D was made by Andria C. Schibler (a previous 
graduate student from Dr. Sharon Dent’s lab, UT M.D. Anderson Cancer Center). 
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3.6 Conclusions  
        In this study, we confirm that ATXN7 strongly stimulates DUB activity. Importantly, 
we demonstrate that ATXN7 with 92 Q residues at the N terminus (ATXN7-92Q NT) 
does not directly impair DUBm activity in vitro but that ATXN7-92Q NT is highly insoluble 
when not assembled into the DUBm. Co-overexpression of other DUBm subunits inhibits 
ATXN7-92Q aggregation in vitro and in human astrocytes. In addition, aggregates 
initiated by overexpression of ATXN7-92Q sequester ATXN7L3 and lead to increased 
global levels of H2Bub. Co-overexpression of ATXN7L3 and ENY2 with ATXN7-92Q 
ameliorates this effect. Consistent with these findings, H2Bub levels were elevated in the 
cerebellums of mice in a SCA7 mouse model, indicating that the impairment of DUBm 
activity might contribute to SCA7 disease. In conclusion, our findings suggest that 
ATXN7-poly(Q) causes SCA7 not by reducing USP22 activity per se but by forming 
aggregates that sequester DUBm components away from their substrates.    
 
3.7 Discussion    
The role of hallmark nuclear aggregates caused by polyQ expansions in the 
pathogenesis of neurodegenerative diseases is still under debate (Todd and Lim, 2013). 
Some studies suggest that nuclear inclusions are cytotoxic, while others indicate that 
they might be cytoprotective by functioning to sequester the misfolded disease proteins 
(Arrasate et al., 2004; Takahashi et al., 2008; Yang et al., 2002). Our data demonstrate 
that although polyQ expansions in ATXN7 have no effect on the assembly and 
enzymatic activity of the SAGA DUBm in vitro, they promote aggregation in vivo, further 
sequestering crucial activators of USP22 activity away from H2Bub and other substrates.  
Our data, then, indicate that the nuclear aggregates cause a loss of effective function of 
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ATXN7-polyQ and associated proteins in vivo, favoring a cytotoxic rather than a 
cytoprotective role for the nuclear inclusions observed in SCA7 disease (Figure 13D).    
  
3.7.1 Nuclear aggregates caused by polyQ expansions are cytotoxic       
      Our findings are consistent with previous studies that indicate that aggregates 
induced by ATXN7 polyQ and other polyQ proteins cause cytotoxicity, whereas soluble 
forms of these proteins do not. For example, ATXN7 and soluble ATXN7-polyQ similarly 
associate with and equally stabilize microtubules, indicating that polyQ expansions that 
do not affect solubility do not affect cytoplasmic functions of ATXN7 (Nakamura et al., 
2012).  
        At least two parameters affect ATXN7-polyQ solubility. SUMOylation attenuates the 
cellular toxicity of ATXN7-polyQ and promotes solubility (Janer et al., 2010).  In addition, 
chaperone proteins, such as Hsp70 and Hsp40, promote polyQ protein solubility through 
assisting refolding of denatured and aggregated proteins in an ATP-dependent fashion 
(Hartl and Hayer-Hartl, 2002). Overexpression of Hsp70 and Hdj1/Hsp40 also 
significantly promote solubility and suppress the neurotoxicity of polyQ-expanded 
proteins in a SCA3 fly model (Chan et al., 2000).  
        Protein misfolding and aggregation can trigger autophagy, a process that plays 
essential, protective roles in neurons (Wong and Cuervo, 2010a, b). Emerging evidence 
indicates that autophagy may be dysfunctional in polyQ diseases (Cheung and Ip, 2011).  
Aggregation of ATXN7-polyQ impairs p53 driven autophagy by sequestering p53-FIP200 
complexes, leading to accumulation of neuronal protein inclusions and 
neurodegeneration (Yu et al., 2013). Sequestration of CREB binding protein (CBP) into 
polyQ aggregates contributes to neuronal toxicity in Huntington’s disease by interfering 
with CBP-mediated transcription (McCampbell et al., 2000; Nucifora et al., 2001). Also, 
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DnaJB1 is sequestered into nuclear inclusions of polyQ Ataxin3 in SCA3 (Seidel et al., 
2012), and Huntingtin polyQ inclusions sequester the Sis1p/DnaJB1 chaperone to 
interfere with nuclear degradation of cytosolic proteins (Park et al., 2013).  All of these 
studies point to the importance of preventing or reversing polyQ-induced aggregations in 
neurodegenerative diseases. 
 
3.7.2 Associations with other subunits of DUBm improves the solubility of ATXN7-
92Q 
        Interestingly, we observe that the solubility of ATXN7-92Q in insect cells is 
improved upon incorporation into the DUBm.  Consistent with these findings, co-
overexpression of ATXN7L3 and ENY2 in human astrocytes suppressed ATXN7-92Q 
aggregation, indicating that imbalances in the levels of the polyQ protein relative to the 
levels of the other DUB components may contribute to disease development. Samara et 
al (Samara et al., 2010) proposed that ATXN7 polyQ expansions would either disrupt 
interactions with other DUBm subunits and compromise the deubiquitinating activity, or 
would cause ATXN7 to aggregate, consequently preventing association with the other 
DUBm subunits. Despite the fact that the position of polyQ in yeast Sgf73 is different 
from that in mammalian ATXN7, our experiments favor the latter hypothesis, as we show 
that the presence of polyQ expansions do not affect the assembly or the activity of the 
DUBm in vitro. An intriguing interaction between the N-terminal portion of Sgf73, Sgf11 
and Sus1 in yeast stabilizes the assembly of the DUB module and could explain how 
over expression of the mammalian counterparts of Sgf11 and Sus1, ENY2 and 
ATXN7L3, promote the solubility of polyQ ATXN7 (Kohler et al., 2010). The interaction of 
Ubp8 with Sgf73 does not require the N-terminal tail of Sgf73 that contains only a few 
residues upstream of the H1 helix in yeast. This part of the protein is, however, 
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fundamental in generating a three-protein junction between the N-terminal H1 helix of 
Sgf11, the C-terminal H5 helix of Sus1 and the N-terminal H1 helix of Sgf73, through the 
coordination of hydrophobic residues that come into close proximity (Kohler et al., 2010). 
Although structural information for mammalian ATXN7 is lacking, the N-terminal tail of 
the protein could be involved in similar interactions with ATXN7L3 and ENY2, and the 
subsequent aggregation caused by the presence of the polyQs might be prevented 
when these associations are formed. Although the degree of structural and functional 
conservation is significantly high between the yeast and the mammalian DUB module 
(Lang et al., 2011), the crystal structure of the mammalian DUB module would greatly 
enhance our understanding of the actual interfaces between the different subunits, and 
how they contribute to the function and solubility of the module.  
        PolyQ ATXN7 has also been reported to have an extended half-life relative to non-
expanded ATXN7 (Yvert et al., 2001). Over time, accumulation of ATXN7-polyQ likely 
promotes aggregation and sequestration of DUBm components.  This process might 
explain the delayed onset of SCA7 and also the inverse relationship between polyQ 
length and age of disease onset. Limiting amounts of DUBm subunits in neural or retinal 
cells could also explain why these specific cell types selectively degenerate in SCA7. 
 
3.7.3 Nuclear aggregates caused by ATXN7-polyQ sequester both enzymatic 
subunits of SAGA complex 
        We have previously shown that that loss of Gcn5 functions contributes to SCA7 
progression in a SCA7 mouse model (Chen et al., 2012) and Gcn5 is present in 
aggregates formed by ATXN7-92Q (McCullough et al., 2012).  Our analysis of global 
histone levels purified from human astrocytes is in agreement with that of McCullough et 
al, in that H2Bub levels increase in the presence of the ATXN7-92Q overexpression with 
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no change in global levels of H3K9/K14ac. The fact that ATXN7L3, a crucial activator of 
USP22 activity, is also sequestered into aggregates in the presence of ATXN7-polyQ 
mutant can explain the defect in the deubiquitinating activity of the complex and the 
increased levels of H2B ubiquitination observed both globally (present study), as well as 
on specific promoters (McCullough et al., 2012). Although the fact that Gcn5 is also 
sequestered into nuclear foci, the lack of change in levels of H3K9/K14 acetylation might 
be explained by functional compensation through other HATs existed in human 
astrocytes, like PCAF.  Interestingly, treatment of the human astrocytes with the HDAC 
inhibitor TSA rescued the DUB activity defect, but also increased the number of nuclear 
foci. McCullough et al, suggested that TSA treatment induces the aggregation of mutant 
ATXN7 into nuclear foci, making room for the endogenous wild type form of the protein 
to work more efficiently towards H2B deubiquitination. Our current results propose a 
different mechanism, wherein TSA might enhance expression of other DUB module 
components, thereby enhancing solubility of ATXN7 polyQ.  Our data clearly show that 
overexpression of ATXN7L3 and ENY2 promotes the solubility of ATXN7-polyQ, 
possibly facilitating its incorporation in the SAGA complex, and restoring DUB activity.  
        Sequestration of both enzymatic centers in SAGA into nuclear aggregates upon 
ATXN7-polyQ expansion likely plays a key role in SCA7 progression and development. 
However, our findings strongly suggest that therapies designed to improve the 
acetyltransferase or the deubiquitinating activity of SAGA may have limited success in 
curing the symptoms of SCA7 disease unless they also inhibit polyQ expanded ATXN7 
aggregation. 
   
 
 
 
68 
Chapter 4: Defining the role of Usp22 in SCA7 disease through establishing a 
Usp22 conditional knockout mouse model 
 
4.1 Establishment of USP22 conditional knockout mouse  
        Our published data demonstrated that loss of Gcn5 accelerates cerebellar Purkinje 
cell and retinal degeneration in a SCA7 mouse model (Chen et al., 2012). Moreover, our 
latest results above showed that polyQ expansion in ATXN7 does not affect the 
assembly or enzymatic activity of the SAGA DUBm in vitro. However, in vivo, ATXN7-
polyQ mutant impairs DUB activity reflected by increase of global H2Bub through 
forming aggregates to sequestrate DUBm components away from their substrates (Lan 
et al., 2015), indicating that ATXN7-polyQ mutant likely contributes to SCA7 by indirectly 
impairing DUB activity. Alternatively, the polyQ expansion itself might be toxic, 
irregardless of its affects on USP22 activity.  Here, I propose to define the role of Usp22 
in SCA7 through deletion of Usp22 in Purkinje cells and/or Bergman glia, both of which 
are involved in SCA7 pathogenesis (Bellamy, 2006; Custer et al., 2006; Garden et al., 
2002). 
        To establish a Usp22 conditional knockout mouse model, we obtained sperm from 
a mouse line generated by the Knockout Mouse Project (KOMP) 
(https://www.komp.org/). This mouse line contains the Usp22FloxFRT allele, in which 
exon2 of Usp22 is flanked by loxP sites, and FRT cassette is inserted into the intron 1 of 
Usp22, terminating the transcription of Usp22 (Figure 14A). We sent these sperm to the 
MDACC Genetically Engineered Mouse core facility in Houston, where in vitro 
fertilization was performed. We obtained 12 mice by in vitro fertilization. 6 out of the 12 
mice contain the Usp22FloxFRT allele (named Usp22FloxFRT/+ mouse), as genotyped 
by PCR with the specific primers provided by the KOMP (Figure 14A and B). We further 
crossed these Usp22FloxFRT/+ mice with Flpase mice obtained from the Jackson Lab 
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and then examined the deletion of FRT cassette in their pups (Figure 14C). We identified 
that 24 out of 36 pups are positive for the recombined allele by PCR genotyping, 
indicating the deletion of FRT cassette (Figure 14A and C). These positive pups are 
hereafter named Usp22Flox/+ mice. Then we intercrossed Usp22Flox/+ mice and 
examined the frequencies of their pups with WT, Flox/+ and Flox/Flox genotypes. We 
obtained 41 pups (WT : Flox/+ : Flox/Flox is 8: 24: 9) as F1. At the same time, we 
crossed Usp22Flox/+ mice with two specific Cre lines (Pcp2-Cre and hGFAP-Cre). 
Crossing with Pcp2-Cre and hGFAP-Cre mice will cause the specific deletion of Usp22 
in Purkinje cells and Bergmann glia, respectively. Finally, these mice with specific loss of 
Usp22 will be monitored and identified for SCA7 linked “Ataxia” phenotypes (Chen et al., 
2012). Pcp2-Cre mediated recombination is fully established by 2-3 weeks after birth 
(Barski et al., 2000), so mice with Usp22 deletion in Purkinje cells will be monitored for 
“Ataxia” phenotype since 3 weeks after birth;  hGFAP-Cre mediated recombination is 
fully established after birth (Zhuo et al., 2001), mice with Usp22 deletion in Bergmann 
glia will be monitored for “Ataxia” phenotype since 2-3 weeks after birth. Currently, this 
project is still ongoing. 
 
4.2 Future directions 
        We will examine whether or not Purkinje cell-specific and Bergmann glia-specific 
Usp22 deletion affect lifespan by performing survival analysis using these mice. 
Moreover, we will perform footprint analyses (Carter et al., 1999) and rotorod analyses 
(Jafar-Nejad et al., 2011) to examine whether these cell type-specific Usp22 null mice 
exhibit “Ataxia” phenotype compared with WT mice (Chen et al., 2012). To validate the 
deletion of Usp22, we will carry out immunohistochemistry and in situ hybridization 
experiments. If we observe SCA7 related “Ataxia” phenotypes in these cell type-specific 
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Usp22 null mice, we will further perform hematoxylin and eosin Y (H&E) staining to 
examine the histological structure of their cerebellums.  To further characterize the 
potential Purkinje cell and Bergmann glia pathology, we will also perform 
immunofluorescence experiments using the cerebellar sections by anti-calbindin 
(Purkinje cell marker) and anti-GFAP (Bergmann glia marker) antibodies. To identify the 
related molecular pathways, we will examine the potential transcriptional change of well-
documented target genes involved in SCA7 by qRT-PCR. Finally, since our lab have 
generated Usp22 conditional overexpression mouse model, we can use this mouse 
model to rescue the potential SCA7 phenotypes caused by the specific Usp22 loss in 
Purkinje cell and/or Bergmann glia. On the other hand, if we do not observe any SCA7 
related phenotypes in these cell type-specific Usp22 null mice, this could be explained 
be several reasons: 1) Other Usps compensate the loss of Usp22; 2) Defective Usp22 
DUB activity is a passive rather than a causative effect in SCA7 disease. 3) PolyQ 
stretch itself is cytotoxic. 
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Figure 14: Establishment of Usp22 conditional knockout mouse. 
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Figure 14: Establishment of Usp22 conditional knockout mouse. 
(A) Diagram of an Usp22 knockout first allele, this knockout first allele is initially a null 
form, but can be converted to a conditional allele via Flpase recombination. The specific 
primers for genotyping are indicated. To obtain the Usp22 conditional allele, the mice 
containing this allele are crossed with Flpase mice to delete the FRT cassette, resulting 
in floxed mice. The Exon2 of Usp22 gene, which encodes part of ZnF domain of Usp22 
protein required for the activation of Usp22 DUB activity, will be deleted after Cre 
recombination.  (B) Genotyping of the Usp22FloxFRT/+ mice (generated by in vitro 
fertilization) by PCR with the indicated primers. The band of 648 bp represents the PCR 
product of Usp22FloxFRT mice, and no band corresponds to the WT mice. mES cells 
containing the Usp22FloxFRT allele serves as positive control. (C) Validation of FRT 
cassette deletion after Flpase recombination (cross with Flpase mice) by PCR with the 
indicated primers. The band of 489 bp represents the PCR product of WT allele, and the 
slow migrating band of 623 bp indicated by “arrow” corresponds to Usp22Flox/+ mice. 
mES cells containing the Usp22FloxFRT allele without and with Flpase treatment serve 
as negative control and positive control, respectively. An Usp22FloxFRT/+ mouse 
(named 6602) serves as negative control. Amanda M Martin (Technician), and Andrew P 
Salinger (lab manager) from Dr. Sharon Dent’s lab (UT M.D. Anderson Cancer Center) 
help me set up the mouse breeders and make mouse genomic DNA. I did the 
genotyping by PCR. 
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Chapter 5: USP44 is an integral component of N-CoR that contributes to target 
gene repression by modulating H2Bub1 levels 
Contents of this chapter are based on Xianjiang Lan, Boyko S. Atanassov, Wenqian Li, 
Ying Zhang, Laurence Florens, Ryan D. Mohan, Michael P. Washburn, Jerry L. 
Workman, and Sharon Y. R. Dent* USP44 is an integral component of N-CoR that 
contributes to target gene repression by modulating H2Bub1 levels. In revision for 
publication. 
 
 
5.1 USP44 is a subunit of the N-CoR complex 
        USP44 is implicated in ES cell differentiation, DNA damage repair, and cancer 
development (Fuchs et al., 2012; Liu et al., 2015; Mosbech et al., 2013; Stegmeier et al., 
2007; Zhang et al., 2012). As a deubiquitinating enzyme, decreased USP44 levels were 
used to account for a global increase in H2Bub levels during ES cell differentiation 
(Fuchs et al., 2012). However, USP44 alone is not active, whether USP44 can directly 
deubiquitinate histone H2B and what the other partners required for the activation of its 
DUB activity are not known. 
        To further define USP44 functions, I tested the ability of recombinant USP44 to 
deubiquitinate H2Bub1 in vitro. Like most other H2B DUBs identified to date (USP22, 
USP27x, USP49 and USP51), I found that recombinant USP44 is not active by itself and 
association with CETN2 is also not active (Figure 15). The protein domain structure of 
USP44 is very similar to that of the other DUBs (Figure 16A), all of which require 
association with partner proteins for full enzymatic activity (Lang et al., 2011; Zhang et 
al., 2013), I reasoned that USP44 might also require partners to acquire enzymatic 
activity toward H2Bub1. To test this idea, I used a proteomic approach to identify USP44 
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interacting proteins. I isolated nuclear extracts from 293T cells that stably express 
USP44 fused with N-terminal FLAG and HA affinity tags (FH-USP44), and then 
performed tandem affinity purification (TAP) followed by MudPIT analysis to uncover 
USP44 associated proteins. As expected, CETN2 (centrin2), the only known USP44 
interacting protein (Zhang et al., 2012), was one of the major proteins we identified 
(Figure 16B). Surprisingly, the majority of the other USP44-associated proteins we 
identified are subunits of the N-CoR complex, including TBL1X, TBL1XR1, HDAC3, 
NCOR1 and NCOR2 (also called SMRT) (Yoon et al., 2003). Moreover, a number of 
proteasomal subunits, including PSMC1, PSMC2, PSMC4 and PSMC5, which associate 
with N-CoR for its degradation (Perissi et al., 2004), were also identified as USP44 
interacting proteins, none of these USP44 partners were detected in the FH-vector 
control purified in parallel (Figure 16B).  
        To further explore possible connections between CETN2, USP44, and N-CoR, we 
performed TAP of FH-tagged CETN2 followed by MudPIT analysis.  Consistent with our 
results above, USP44 was detected as a CETN2 interacting protein. Moreover, RAD23B 
and XPC, both of which are known to form a complex with CETN2 in the nucleus (Nishi 
et al., 2005), were also detected in the CENT2 precipitated fractions. However, N-CoR 
complex subunits were not detected in the CETN2 purification, and XPC and RAD23B 
were not found in USP44 precipitated fractions (Figure 16B). Thus, these data indicate 
that USP44 is likely part of two separate complexes, associated with either CETN2 or N-
CoR. 
        To validate our MudPIT results, I immunoprecipitated ectopically expressed USP44 
from 293T nuclear extracts and blotted the precipitated fractions for TBL1X, TBL1XR, 
NCOR1 or HDAC3. These experiments confirmed interactions between endogenous N-
CoR complex subunits and FH-USP44, but not another H2Bub1 DUB, USP22 (Figure 
16C). Reciprocal immunoprecipitation using a TBL1X antibody pulled down FH-tagged 
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USP44 (anti-HA blot), as well as other N-CoR complex subunits (Figure 16D). To further 
determine whether USP44 is an integral component of the N-CoR complex, I performed 
gel filtration using FLAG and HA purified USP44 eluates. Immunoblots of column 
fractions showed that USP44 co-purifies with N-CoR subunits (fractions 16 and 17), 
corresponding to the expected molecular weight of the N-CoR complex (1.5-2 MDa) 
(Yoon et al., 2003). Importantly, CETN2 was found mostly in fractions that contained 
little or no N-CoR subunits (fractions 18-23) (Figure 16E), again indicating that USP44 
forms separate complexes with these proteins. Further cell fractionation experiments 
confirmed associations of USP44 and N-CoR complex components with chromatin 
(Figure 17). Collectively, these results demonstrate that USP44 associates with the N-
CoR complex independently of CETN2 in the nucleus, indicating that this DUB likely 
functions in multiple processes. 
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Figure 15: Recombinant USP44 alone is not active and interaction with CETN2 or 
TBL1X and/or TBL1XR1, and/or PSMC5 does not affect the DUB activity of USP44.  
(A) Colloidal Coomassie staining of purified USP44 (WT and catalytic mutant) and 
USP44-CETN2 complex from bacurovirus infected insect cells. (B) Purified USP44 alone 
or together with CETN2 were used for in vitro DUB assay with purified core histones as 
substrate. Total H2B was used as a loading control. USP44 was HA-tagged and CETN2 
was FLAG-tagged. 1x and 2x indicate the amount of purified enzymes used in the assay. 
All components were probed with indicated antibodies.  
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Figure 16: USP44 associates with N-CoR complex. 
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Figure 16: USP44 associates with N-CoR complex. 
(A) Schematic representation of protein domain structure of USP44, USP49, USP22, 
USP27x, and USP51 (B). Normalized Distributed Spectral Abundance Factor (dNSAF) 
of partial CETN2 associated polypeptides and USP44 associated polypeptides identified 
by MudPIT analysis. Bait proteins are highlighted in red, components of CETN2-XPC 
complex are highlighted in blue, and components of N-CoR comlex are in green and 
dark.  (C) Immunoprecipitation (IP) from nuclear extract (NE) of NFH-USP44 293T cells 
using FLAG beads. (NFH, N-terminal FLAG and HA tags). pINTO-NFH vector cells 
serves as negative control. Bound proteins were resolved on SDS-PAGE and analyzed 
by western blot with indicated antibodies. (D) Immunoprecipitation (IP) from nuclear 
extract (NE) of NFH-USP44 293T cells using TBL1X antibody, followed by western blot 
with inidicated antibodies. (E) Gel filtration analysis of tandem FLAG and HA-purified 
NFH-USP44 complexes. Fractions were resolved on SDS-PAGE followed by 
immunoblot with indicated antibodies. Multidimensional Protein Identification Technology 
(MudPIT) analysis in Figure 17B was performed by Ying Zhang, Laurence Florens from 
Dr. Michael P. Washburn lab (Stowers Institute for Medical Research, Kansas City, 
Missouri, USA). 
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Figure 17: USP44 mainly associates with chromatin in the nucleus, together with 
N-CoR subunits.  
Cytoplasmic, soluble nuclear, and chromatin fractions were isolated from NFH-USP44 
293T cells. Fractions were resolved on SDS-PAGE and blotted with the indicated 
antibodies.β-tubulin serves as a marker for cytoplasmic fraction, H2A and H4 serves as 
markers for chromatin fraction. S2: cytoplasmic fraction; S3: soluble nulcear fraction; P3: 
chromatin fraction. 
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 5.2 USP44 interacts directly with WD40 repeats in TBL1X and TBLXR1  
        Several USPs interact with WD40-containing proteins (Villamil et al., 2013). For 
example, WDR48 interacts with USP1, USP12 and USP46 to activate their DUB activity 
(Cohn et al., 2009) (Yin et al., 2015). Interestingly, two N-CoR components, TBLX and 
TBL1XR1, contain WD40 repeats  (Figure 18A). Moreover, TBL1X and TBL1XR1 were 
the top non-CETN2 USP44 interacting proteins detected in our MudPIT analyses (Figure 
18B). To determine whether USP44 interacts directly with TBLX1 or TBLXR1, I 
performed immunoprecipitation (IP) experiments using recombinant HA-USP44 and 
FLAG-TBL1X/TBL1XR1 from baculovirus infected insect cells. Both TBL1X and 
TBL1XR1 interacted with USP44, alone and together (Figure 18B). TBL1X and 
TBL1XR1 contain multiple domains, including LisH domains, F-box domains, and WD40 
repeats (Figure 18A). Previous studies demonstrated that the N-terminal of LisH and F-
box domains bind to histones H2B and H4 and are also required for assembly of the N-
CoR complex (Oberoi et al., 2011; Yoon et al., 2003).  To determine whether these 
domains or the C-terminal WD40 repeats of TBL1X/TBL1XR1 are required for interaction 
with USP44, I created expression constructs for truncated forms of TBLXR1 that 
contained either the N-terminal LisH  and F-box motifs (F1) or the C-terminal WD40 
repeats (F2) fused to Gal4 (Figure 18A).  Introduction of these constructs into 293T cells 
expressing FH-USP44 and subsequent FLAG-immunoprecipotations revealed that full 
length TBLXR1 and the C-terminal fragment interacted with USP44, but the N-terminal 
TBL1XR1 construct did not (Figure 18C). These results indicate that the WD repeats in 
TBXLR1 are both necessary and sufficient for USP44 interaction. Nevertheless, an in 
vitro reconstituted USP44, TBL1X and TBLXR1 containing complex did not show 
obviously different DUB activity toward H2Bub1 relative to USP44 alone (Figure 19), 
indicating that the interactions with TBL1X and TBLXR1 are required for USP44 
association with N-CoR but are not sufficient for USP44 activation. 
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Figure 18: WD40 repeats of TBL1X/R1 are required for the association of USP44 
with N-CoR complex.  
(A) Schematic of TBL1X and TBL1XR1 domains. The deletion constructs of TBL1XR1 
were as indicated. (B). Immunoprecipitations using lysates from Sf21 cells expressing 
the proteins indicated, using HA beads followed by western blot using HA or FLAG 
antibodies. (C). NFH-USP44 cells were transiently transfected with the indicated GAL4-
TBL1XR1 truncations. Immunoprecipitations using the cell lysates using FLAG beads 
followed by western blot using HA or GAL4 antibodies. 
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Figure 19: Recombinant USP44 interaction with TBL1X and/or TBL1XR1, and/or 
PSMC5 does not affect the DUB activity of USP44. 
Purified USP44 alone or together with TBL1X, and/or TBL1XR1, and/or PSMC5 were 
used for in vitro DUB assay with purified core histones as substrate. Total H2B was used 
as a loading control. All components were probed with indicated antibodies. 
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5.3 USP44 deubiquitinates H2Bub1 as part of N-CoR  
        To determine whether USP44 is active towards H2Bub1 in vivo, I depleted USP44 
in 293T cells using shRNAs (Figure 20A). Consistent with previous reports using ES 
cells (Fuchs et al., 2012), depletion of USP44 led to noticeable (~2 fold) increase in 
H2Bub1 levels in 293T cells (Figure 20A and B).  To further address USP44 effects on 
H2Bub1, I overexpressed either wild type (WT) or a catalytic mutant (C282A) of USP44 
(Figure 20C). Overexpression of WT USP44 led to an obvious decrease H2Bub1 levels, 
whereas overexpression of the C282A mutant did not (Figure 20C and D).  
        To more directly test the ability of USP44 to deubiquitinate H2Bub1, I utilized our 
TAP purified FH-USP44-N-CoR complex for in vitro DUB assays using purified core 
histones as substrate (Figure 20E). H2Bub1 immunoblots indicate that relative to a FH-
vector control purified in parallel, increased amounts of FH-USP44-N-CoR in the 
reaction led to decreased H2Bub1. To further test whether DUB activity is associated 
with the N-CoR complex, I repeated these experiments using TAP-purified N-CoR from 
293T cells stably expressing FH-TBL1X (Figure 21). Incubation of the FH-TBL1X-N-CoR 
complex with purified histones again led to decreased levels of H2Bub1 (Figure 20F). 
Moreover, association with CETN2 did not affect the DUB activity of USP44 in vitro. 
These experiments indicate that USP44 is an active deubiqutinase when associated with 
the N-CoR complex.  
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Figure 20: USP44-N-CoR complex deubiquitinates H2B in vivo and in vitro. 
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Figure 20: USP44-N-CoR complex deubiquitinates H2B in vivo and in vitro. 
 (A) 293T cells were infected with pGIPZ shControl or shUSP44 lentivirus. After 48 hours 
infection, the knockdown efficiency of USP44 was detected by quantitative real-time 
PCR with two different pairs of USP44 primers. GAPDH was used as internal control for 
normalization. Each value is the mean of three technical replicates with error bars 
representing the standard deviation. (B) Depletion of USP44 leads to marked increase of 
global H2Bub1. H2B and Ponceau serve as the loading control. Different sample 
amounts (1× and 2×) were analyzed (C) Expression levels of WT or catalytically inactive 
USP44 proteins in 293T cells. (D) Expression of WT USP44, rather than catalytic 
inactive USP44 reduces global levels of H2Bub1 in 293T cells. Different sample 
amounts (1× and 2×) were analyzed (E, F) Sequential FLAG and HA purified USP44 
complex or TBL1X complex from 293T cells was used for in vitro DUB assay using 
histones as substrate. Both complexes show moderate activity towards H2Bub in vitro. 
Different amounts of USP44/N-CoR complex (1× and 2×) were used for the assay. Blots 
were quantified using ImageJ software in this and all other figures in this article.  
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Figure 21: FH-TBL1X-N-CoR complex purification from 293T cells.  
Silver stain and immunoblot analyses to confirm the subunits of N-CoR complex. FH-
TBL1X bait protein is indicated by black line. USP44, NCOR and HDAC3 were probed 
by specific antibody, respectively. 
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5.4 USP44 enhances the repressive activity of N-CoR  
        Given that N-CoR functions as a transcriptional repressor through recruitment of 
the histone deacetylase HDAC3 (Wong et al., 2014), I next determined whether USP44 
also contributes to N-CoR functions using a genome integrated luciferase reporter 
system as previously described (Vaquero et al., 2004) (Figure 22A). I generated stable 
293 T-Rex cells (Vaquero et al., 2004) containing doxycycline-inducible expression 
constructs for GAL4-TBL1X, GAL4-TBL1XR1 or GAL4 alone. As expected, luciferase 
expression and activity was repressed upon induction of GAL4-TBL1X or GAL4-
TBL1XR1 (Figure 22B). I next examined the contribution of USP44 and TBL1XR1 to the 
repressive activity of GAL4-TBL1XR1. Quantitative real-time PCR (qRT-PCR) and 
immunoblot analyses confirmed the knockdown (KD) efficiency of USP44 and GAL4-
TBL1XR1 (Figure 22C and D). As expected, depletion of TBL1XR1 led to a marked 
increase of luciferase activity (Figure 22E). Interestingly, depletion of USP44 also led to 
a moderate increase of luciferase activity (Figure 22E). As GAL4-TBL1XR1 is required 
for recruitment of both USP44 and HDAC3, the enhanced effect of TBLXR1 KD likely 
reflects loss of both HDAC3 and USP44. 
        I next confirmed promoter recruitment of USP44 together with the N-CoR complex 
by ChIP-qPCR.  As expected, upon doxycycline induction, GAL4-TBL1XR1 and FLAG-
HA-USP44 were both recruited to the TK promoter that drives the luciferase reporter 
(Figure 22F). In addition, histone H3 acetylation at lysines 9 and 14 (H3K9/14ac), the 
main substrate of HDAC3 (Bhaskara et al., 2010), was reduced, consistent with 
HDAC3/N-CoR recruitment (Figure 22G). Moreover, H2Bub1 was also reduced (Figure 
22H), consistent with USP44/N-Co-R recruitment at this locus. Collectively, these results 
suggest that USP44-N-CoR complex creates a compact chromatin environment by 
removing histone acetylation and H2Bub1, further exerting repressive activity for 
transcription.  
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Figure 22: USP44 facilitates the repressive activity of N-CoR complex through 
deubiquitinating H2B. 
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Figure 22: USP44 facilitates the repressive activity of N-CoR complex through 
deubiquitinating H2B. 
(A) Schematic of the luciferase reporter system. (B) Fold change in luciferase activity in 
cells expressing GAL4, GAL4-TBL1XR1, and GAL4-TBL1X, after 24 hours doxycycline 
(100 ng/ml) induction. Each value is the mean of three independent measurements with 
error bars representing the standard deviation. Expression levels of all GAL4-tagged 
proteins are shown at the bottom without (−) and with (+) induction. qRT-PCR (C) and  
immunoblots (D) demonstrating the efficient silencing of USP44 and TBL1XR1 in GAL4-
TBL1XR1 cells with or without induction. (E) Fold change in luciferase activity in GAL4-
TBL1XR1 cells upon knockdown of USP44 or TBL1XR1. Cells were infected by pGIPZ 
shcontrol, shUSP44 or shTBL1XR1 lentivirus for two days and then 100 ng/ml 
doxycycline was used to induce GAL4-TBL1XR1 expression. After 24 hours induction, 
luciferase activity was measured. Each value is the mean of three independent 
measurements with error bars representing the standard deviation. * p-value < 0.05 and 
** p-value < 0.01 by two-sided t-test, compared with pGIPZ shcontrol. (F-H) ChIP 
followed by qRT-PCR using the antibodies indicated and GAL4-TBL1XR1 cells without 
or with doxycycline induction after transfection with pCAG-USP44-C-FH vector. ChIP 
enrichment is shown as percentage of input, histone H3 or histone H2B. All values 
represent the average of three technical replicates with error bars indicating standard 
deviation.  
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5.5 USP44-N-CoR complex links H2Bub1 to invasiveness of triple negative breast 
cancer cells  
        USP44 (protein level) is highly expressed in breast cancer stem cells, and it may 
contribute to breast cancer aggressiveness (Liu et al., 2015). TBL1XR1 (protein level) is 
overexpressed and involved in aggressiveness of malignant breast cancer cells, 
including MDA-MB-231 triple negative cells (Li et al., 2014). Interestingly, I find that 
USP44 mRNA level is significantly higher, and H2Bub1 levels are lower (but H2Aub1 
levels are similar) in MDA-MB-231 cells compared to MCF10A normal breast epithelial 
cells (Figure 23A and B). Depletion of USP44 significantly impaired the invasiveness of 
MDA-MB-231 cells in vitro and led to an increase of global H2Bub1 levels (Figure 23C, 
D and E). Our results showed depletion of TBL1XR1 impaired the invasiveness of breast 
cancer cells (Figure 24), which are consistent with a previous study (Kadota et al., 
2009). Accordingly, I found that depletion of TBL1XR1 also led to increased levels of 
H2Bub1 and moderately increased levels of H3K9/14ac, but no obvious change of 
H2Aub1 levels (Figure 23F and G). Together our results indicate that USP44 contributes 
to N-CoR functions in regulating gene expression and in modulating the invasiveness of 
triple negative breast cancer cells. 
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Figure 23: USP44 regulates the invasiveness of breast cancer cells. 
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Figure 23: USP44 regulates the invasiveness of breast cancer cells. 
(A) qRT-PCR analysis of USP44 mRNA in MCF10A cells and MDA-MB-231 cells. 
GAPDH serves as internal control. (B) Histones was purified from MCF10A and MDA-
MB-231 cells, and resolved on SDS-PAGE and blotted with anti-H2Bub or anti-H2Aub 
antibody. Total H2B or H2A blots were used as loading control. (C) MDA-MB-231 cells 
stably infected with pGIPZ shcontrol or two different shUSP44 lentiviruses were used to 
perform transwell invasion assay. After 48 hours incubation, cells invading to the bottom 
of Matrigel chambers were stained with crystal violet. (D) qRT-PCR to demonstrate 
efficient silencing of USP44 in MDA-MB-231 cells. (E) Histones purified from MDA-MB-
231 cells stably infected with pGIPZ shcontrol or shU SP44 lentiviruses were resolved 
on SDS-PAGE and blotted with indicated antibodies. (F) Immunoblots to demonstrate 
silencing efficiency of TBL1XR1 in MDA-MB-231 cells. Two different TBL1XR1 shRNAs 
were used. (G) Histones purified from MDA-MB-231 cells stably infected with pGIPZ 
shcontrol or shTBL1XR1 lentiviruses were resolved on SDS-PAGE and blotted with 
indicated antibodies. Total H2B, H3 or H2A serves as loading control, Different sample 
amounts (1× and 2×) were analyzed. 
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Figure 24: Ablation of TBL1XR1 impairs the invasiveness of MDA-MB-231 cells. 
MDA-MB-231 cells stably infected with pGIPZ shcontrol or two different shTBL1XR1 
lentiviruses were used to perform transwell invasion assay. After 48 hours incubation, 
cells invading to the bottom of Matrigel chambers were stained with crystal violet and 
imaged. Three independent experiments were performed and representative views are 
showed above. 
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Figure 25: Model of the function of USP44-N-CoR complex in cells. 
On the gene promoters, N-CoR complex bind chromatin through TBL1X/TBL1XR1, and 
directly recruits USP44 to deubiquitinate histone H2B and HDAC3 to deacetylate histone 
H3K9/14, both of which work together to repress transcription. 
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5.6 Conclusions        
       Here we report use of tandem affinity purification and Multidimensional Protein 
Identification Technology (MudPIT) to identify USP44 interacting proteins.  We found 
that USP44 interacts with several components of the Nuclear receptor co-repressor 
complex (hereafter N-CoR complex). As part of N-CoR, USP44 deubiquitinates H2B 
both in vivo and in vitro, and it contributes to N-CoR mediated repression in vivo.   
        USP44 has been reported to be a marker for breast cancer stem cells (Liu et al., 
2015).  We find that USP44 expression is highly increased in triple negative, MDA-MB-
231 breast cancer cells relative to MCF10-A cells. Importantly, depletion of USP44 
markedly impairs the invasiveness of MDA-MB-231 cells and leads to increased global 
H2Bub1 levels. Consistently, depletion of another N-CoR component, TBL1XR1, known 
to be highly expressed in breast cancer cells (Kadota et al., 2009; Li et al., 2014), also 
leads to increased global H2Bub1 levels. Overall, our study demonstrates that USP44 
associates with the N-CoR complex to regulate H2Bub1 levels and impacts the 
invasiveness of breast cancer cells.  
 
5.7 Discussion and future directions 
        The N-CoR complex functions as co-repressor for various transcription factors 
including nuclear receptors through recruitment of HDACs (Wong et al., 2014). Here we 
report that USP44 functions as a second enzymatic subunit of the N-CoR complex and 
that this complex can deubiquitinate histone H2B in vivo and in vitro. Our results indicate 
that both the deubiquitination of histone H2B by USP44 and deacetylation of histone H3 
by HDAC3 contribute to N-CoR mediated transcriptional repression (Figure 25).  
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5.7.1 USP44-NCOR1 complex is a multiple enzymatic subunits containing complex 
        Several chromatin modifying complexes contain multiple activities, as we describe 
here for the USP44-N-CoR complex. The SAGA complex, a well-characterized histone 
modifying complex, contains two enzymes, the histone acetyltransferase Gcn5 and the 
histone deubiquitinase USP22 (Koutelou et al., 2010). Moreover, the MOF-MSL complex 
is composed of the MOF histone acetyltransferase and the MSL E3 ubiquitin ligase (Wu 
et al., 2011). These multiple enzymatic subunits containing complexes reflect how 
complicated networks of chromatin modifying enzymes function coordinately in 
transcription regulation (Workman, 2016).  
        The N-terminal domains of TBL1X and TBL1XR were previously reported to bind 
histone H2B and H4 (Yoon et al., 2003). Here we found that the C-terminal WD40 repeat 
domains of TBL1X and TBL1XR1 are required to recruit USP44. Given that USP44 
functions as a histone DUB, interaction with TBL1X and TBL1XR1 could help USP44 
target its substrate for deubiquitination. However, association with TBL1X and TBL1XR1 
is not enough to activate the DUB activity of USP44 in vitro, indicating that additional 
partners may be required.  Future work will determine which other subunits of N-CoR are 
needed for USP44 activity and the structural basis for its activation. 
        A previous report of global proteomic analyses identified interacting proteins for 75 
human DUBs, including USP44 in whole cell lysates (Sowa et al., 2009). The major 
USP44 interacting proteins identified were CETN2 and a number of mitochondrial 
proteins, such as MRPL40, MRPL23 and MRPL53. The USP44-CETN2 complex is 
known to play an important role in preventing chromosome segregation errors during 
mitosis (Zhang et al., 2012). The function of USP44 in association with mitochondrial 
proteins is not yet clear. However, no subunits of the N-CoR complex were identified, 
which might reflect the use of whole cell extracts rather than nuclear extracts as used in 
our study. Indeed, none of the mitochondrial proteins identified in the previous study 
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were found in our MudPIT analyses. Together, these data suggest that USP44 plays 
multiple roles in different cellular compartments by forming complexes with distinct 
partners. 
        Genome-wide ChIP-seq analyses in human cells show that H2Bub1 is generally 
associated with highly expressed genes, being enriched at 5’ beginning of transcribed 
regions and also broadly distributed throughout gene bodies (Jung et al., 2012; Minsky 
et al., 2008). Several studies have highlighted the important roles of H2Bub1 in 
transcriptional elongation (Fleming et al., 2008; Pavri et al., 2006; Zhang and Yu, 2011).  
However, the role of H2Bub1 at gene promoters is less lucid. It is still an open debate 
whether relatively low H2Bub1 signals at gene promoters reflect enhanced 
deubiquitination activity at this region or low ubiquitination of promoter nucleosomes. In 
yeast, cycles of H2B ubiquitination and deubiquitination are needed for a productive 
switch from transcription initiation to elongation (Henry et al., 2003). Recent studies 
indicate a direct link between H2B deubiquitination at promoter regions and decreased 
transcription in Drosophila and mammalian cells (Kessler et al., 2015; Sussman et al., 
2013). In addition, in vitro analyses using chemically defined nucleosome arrays 
containing recombinant H2Bub1 (Fierz et al., 2011) demonstrated that H2Bub1 can 
disrupt higher-order chromatin architectures, facilitating more open, accessible 
conformations needed for transcription. Our data indicate that USP44-N-CoR complex 
likely represses transcription by removing H2Bub1 via USP44 and histone acetylation 
via HDAC3 at the promoter.    
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 5.7.2 USP44-NCOR1 complex is involved in the regulation of breast cancer 
development 
        Reduced global H2Bub1 levels have been observed in multiple advanced cancers 
including breast cancer, lung cancer, colorectal cancer and seminoma (Fuchs and Oren, 
2014), raising the possibility that high levels of H2Bub1-specific DUBs could play a 
causal role in tumor formation or progression. In support of this notion, USP22, a well-
known H2Bub1 DUB (Zhang et al., 2008), is highly expressed in various aggressive 
cancers and is part of an 11 genes “death from cancer signature” that defines tumors 
with cancer stem cell phenotypes of aggressive growth, metastasis and resistance to 
therapy (Glinsky, 2006). USP44 was reported to be overexpressed in human T cell 
leukemias (Zhang et al., 2011). We report here that USP44 is highly expressed in 
aggressive breast cancer MDA-MB-231 cells, leading to low global H2Bub1 levels and 
contributing to the invasiveness of these cells. Consistent with these findings, another 
essential subunit of the N-CoR complex, TBL1XR1, is also highly expressed in 
advanced breast cancer cells and contributes to their aggressiveness (Li et al., 2014). 
Although N-CoR complex is well documented as a co-repressor for unliganded nuclear 
receptors, we were unable to detect an effect of USP44 KD on the transcription of 
estrogen receptor (ER) target genes in MCF7 cells (data not shown). However, the 
mRNA levels of USP44 in MCF7 cells are very low (data not shown), as they are in 
MCF10-A cells (Figure 23A). The USP44-N-CoR complex, then, may function as co-
repressor for other types of transcription factors in MDA-MB-231 cells that drive 
metastatic behavior. We also cannot rule out the possibility that USP44 has non-histone 
substrates that are important for aggressive cancer phenotypes. 
        Overall, our results suggest that USP44-N-CoR complex may contribute to the 
aggressiveness of triple negative breast cancers through regulating the transcription of 
target genes by modulating the H2Bub1 levels and H3K9/14ac levels at the promoters. 
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However, due to the lack of ChIP grade antibody for USP44, currently, we are not able 
to identify these specific target genes of USP44-N-CoR complex. Additional efforts on 
identifying these target genes likely provide new insights for therapeutic purpose of 
breast cancer.  
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Chapter 6: Discussion 
 
        Histones undergo multiple posttranslational modifications, which play important 
roles in regulating various DNA-templated biological processes including DNA repair, 
DNA replication, and gene expression (Zhou et al., 2011). H2B monoubiquitination 
(H2Bub1) is very conserved from yeast to mammals and plays important roles in 
modulating various genome functions (Smith and Shilatifard, 2010). Dysregulation of 
H2Bub1 is correlated with multiple serious human diseases including neurodegenerative 
diseases and cancers (Weake and Workman, 2008).  
        USP22 of DUBm in SAGA complex is an important H2Bub1 regulator and its DUB 
activity contributes to crucial roles of SAGA complex in regulating gene expression 
(Weake et al., 2008). However, USP22 alone is not active, appropriate structural 
organization of the DUBm is required for activating its DUB activity (Kohler et al., 2010). 
We demonstrated that ATXN7 polyQ mutant indirectly impairs the DUB activity of USP22 
through forming nuclear inclusions to sequester USP22 and other SAGA components 
away from its targets, further contributing to neurodegenerative disease, SCA7. More 
importantly, we discovered that co-overexpression of other DUBm subunits significantly 
promotes the solubility of ATXN7-polyQ mutant and further restores the DUB activity. 
Given that there is still no known cure for SCA7 disease, our data suggest that therapies 
designed to prevent aggregation of ATXN7-polyQ mutant should achieve good effect for 
treating SCA7 and other nuclear inclusions-formed polyQ diseases. 
        Similar to USP22, USP44 is associated with H2Bub1 regulation and is not active by 
itself. Several literatures reported that USP44 is involved in various biological processes 
including DNA damage response, ES differentiation and cancer development (Fuchs et 
al., 2012; Liu et al., 2015; Mosbech et al., 2013; Stegmeier et al., 2007; Zhang et al., 
2012), however, what the other partners required for its DUB activity are and how these 
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partners may dedicate its roles in these biological processes remains to be known. I 
discovered here that USP44 functions as an integral subunit of N-CoR complex and 
contributes to N-CoR-mediated transcriptional repression through deubiquitinating 
H2Bub1, regulating breast cancer aggressiveness.  
        Genome-wide analysis by ChIP-seq in human cells shows that H2Bub1 is broadly 
distributed through the whole gene and associated with highly expressed genes (Jung et 
al., 2012; Minsky et al., 2008), but this modification is involved in both gene repression 
and activation (Shema et al., 2008). My data further highlight the importance of H2Bub1 
regulation via USP22, which is involved in neurodegenerative disease and cancer, and 
via USP44, which is associated with breast cancer progression. Despite the fact that 
both USP22 and USP44 deubiquitinate H2Bub1, they likely regulate distinct target genes 
by occupying different gene loci  to remove H2Bub1. In addition to USP22 and USP44, a 
number of other USPs are also involved in regulating H2Bub1 levels to modulate 
different biological processes including USP3, USP27X, USP42, USP49 and USP51. 
Given that around 95 DUBs exist in human genome, more and more H2Bub1 DUBs, I 
believe, will be identified. There are at least two ways for these H2Bub1 DUBs to play 
roles in distinct biological processes. One is that the same USP forms different 
complexes with different partners like USP44-Centrin2 complex and USP44-N-CoR 
complex. The other is that different USPs forms different complexes with different 
partners like USP22-SAGA complex and USP44-N-CoR complex. In this regard, my 
data indicate that more effort for therapies should be put on specific targeting of USPs in 
terms of USP-related diseases.  
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Chapter 7: Future studies 
 
7.1 Identifying the role of Usp22 in SCA7 disease using Usp22 conditional knock-
out mouse  
        Our published data suggest that impairment of SAGA DUB activity contributes to 
SCA7 development (Lan et al., 2015). To further dissect the molecular mechanism 
underlying defective Usp22 DUB activity in the pathogenesis of SCA7, we decided to 
specifically delete Usp22 in the Purkinje cells or Bergmann glia using Usp22 conditional 
knockout mouse model. 
        As I mentioned in Chapter 4, we have successfully generated Usp22 conditional 
knockout mouse model. Two specific Cre mouse lines will be used to study SCA7 
disease, Pcp2-Cre line and hGFAP-Cre line. Crossing with Pcp-2-Cre mouse line and 
hGFAP-Cre mouse line will lead to specific deletion of Usp22 in Purkinje cells and in 
Bergmann glia, respectively. The cell bodies of Bergmann glial cells are around Purkinje 
cells. Both of Purkinje cells and Bergmann glia locate in the cerebellum and are involved 
in the pathogenesis of SCA7 disease (Custer et al., 2006; Furrer et al., 2011). If we 
detect the SCA7 related phenotype-Ataxia, which can be examined by several behavior 
study approaches and histological methods (Chen et al., 2012; Jafar-Nejad et al., 2011), 
this result will be consistent with our published work, indicating that defective USP22 
DUB activity in cerebellum at least contributes to SCA7 development. On the other hand, 
if SCA7 related phenotypes are not detected in these Usp22 specific null mice, this will 
indicate that other USPs may compensate for the loss of Usp22 in the cerebellum. In this 
regard, we need to generate double or triple USPs specific null mice if other Usps 
conditional knockout mice are available. Another alternative possibility is that defective 
Usp22 DUB activity is a resulting rather than a causative effect in SCA7 disease due to 
the cytotoxicity of polyQ stretch. Consistent with this hypothesis, Adachi et al reported 
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that transgenic mice with an expanded CAG repeat display polyQ nuclear inclusions and 
neuronal dysfunction (Adachi et al., 2001). Dissecting the molecular mechanism of 
SCA7 will help therapeutic design of drugs for targeting impaired DUB activity or polyQ 
stretch.  
 
 
7.2 Identifying the USP44-N-CoR complex gene targets involved in breast cancer 
aggressiveness 
        My data indicate that the USP44-N-CoR complex contributes to the aggressiveness 
of triple negative breast cancer cells through repressing the transcription of target genes 
by deubiquitinating H2Bub1 and deacetylating H3K9/14ac at their promoters. What the 
specific targets of Usp44 are in this context remains to be determined. 
        To identify the potential target genes of USP44-N-CoR complex, we need to 
generate a ChIP-grade USP44 antibody for ChIP-seq experiments using MDA-MB-231 
cells. Since TBL1XR1 ChIP-grade antibody is available, we also need to do TBL1XR1 
ChIP-seq analysis. Comparison of USP44 ChIP-seq and TBL1XR1 ChIP-seq data will 
show the common targets. In addition, RNA-seq analyses upon USP44 depletion and/or 
TBL1XR1 depletion in MDA-MB-231 cells will be performed as well. The common target 
genes with similar transcriptional change will be identified by comparing the USP44 and 
TBL1XR1 RNA-seq data. The direct target gene list of USP44-N-CoR complex will be 
identified through combining the ChIP-seq and RNA-seq data. We will validate several of 
the most confident targets by ChIP-qPCR using USP44, TBL1XR1, HDAC3, H2Bub1 
and H3K9/14ac antibodies. To further confirm the potential roles of these targets in the 
aggressiveness of MDA-MB-231 cells, depletion of these targets followed by invasion 
assay and other aggressiveness related assays will be performed.   
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        In summary, these work emphasize the importance of H2Bub1 regulation in normal 
cells. My work also set a good example on dissecting the molecular mechanism of 
diseases involved in the regulation of chromatin and transcription. 
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